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1 Introduction
1.1 Anatomy and physiology of prostate
Prostate, a masculine unique organ, made up of glandular tissue and muscle tissue, is
located in pelvic cavity. The normal size of prostate is 4cm × 3cm × 2cm. It has four
major physiological functions. Firstly, as a exocrine gland, prostate could secrete the
prostatic fluid, which is a crucial constituent of semen and has an important influence
on the normal physiological function of sperm. Meanwhile, due to its endocrine
function, prostate is involved in the generation of 5α-reductase, which promotes the
transformation of dihydrotestosterone (DHT) from testosterone. With 5α-reductase
inhibited, the hyperplastic prostate tissue would atrophy and this is the reason why
5α-reductase inhibitors are widely used to treat benign prostatic hyperplasia (BPH) in
the clinical practice. In addition, its circular smooth muscle tissues participate in the
formation of internal urethral sphincter so that prostate might be able to control
urination. Besides, urethra and two ejaculation tubes pass through the prostate,
therefore prostate manifests, to a large extent, the feature of basic transportation.
Figure 1. Anatomical divisions and zones of the Prostate (source from the chapter of prostate
cancer from Canadian Cancer society )
As shown in Figure 1, clinically, prostate is divided into four regions: peripheral zone
(PZ), transition zone (TZ), central zone (CZ) and the anterior fibromuscular stroma
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(AFS) [1]. The peripheral zone taking up over 70% part of the prostate is close to
rectum. Prostate cancer often occurs in the peripheral zone, so digital rectal
examination (DRE) is hugely helpful for the diagnosis of prostate cancer. The urethra
is partially surrounded by transition zone, which constitutes 25% of the prostate and
BPH often occurs at this site. As a result of the limitation of prostatic capsule, BPH
patients are always suffering from the symptoms of urinary tract obstruction.
1.2 Epidemiology and pathology of prostate cancer
Prostate cancer (PCa) is one of the most commonly diagnosed malignant tumor
among men all over the world, especially in European countries and the numbers of
estimated new cases and estimated deaths always account for the first place and the
second place after lung cancer in all male malignancies, respectively [2,3]. Hence,
prostate cancer has already become the main culprit for men’s health. Understanding
the pathogenesis of prostate cancer has always been the focus of attention among
urologists, biologists and oncologists.
Unlike other solid tumors, prostate cancer is a highly heterogeneous and multifocal
malignancy, which leads to the complexity of the pathological diagnosis of prostate
cancer [4,5]. Based on the latest 2016 WHO classification of prostate cancer, more
than ten pathological types are referred to, even if the main pathological
classifications of prostate cancer are still acinar adenocarcinoma, squamous cell
carcinoma, neuroendocrine tumor and miscellaneous tumor [6]. In this new
classification version, some unusual pathological types, such as intraductal carcinoma,
need to be specifically mentioned in the routine pathological report as well. In terms
of the pathological grade of prostate cancer, Gleason grading system has been
introduced as one of the most valuable references in making clinical decision for
patients with prostate cancer [7, 8]. With the acquisition of exceeding number of
evidence-based medical evidence, International Society of Urologic Pathology (ISUP)
updated the Gleason grading system in 2014 and its new Grade group was put forward
along with some modifications of Gleason patterns (Figure 2). It is attributed to the
diversity on histological morphology of prostate cancer cells, besides
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Hematoxylin-eosin (HE) staining, immunohistochemical technique is strongly
recommended for the pathological diagnosis of prostate cancer. Antibodies against
CK34ßE12, P63 and AMACR known as P504S, are often used to aid diagnosis of
ambiguous biopsy samples.
Figure 2. Newly Gleason grading system of prostate cancer (source from Chen N, et al [7])
1.3 Contemporary diagnosis in prostate cancer
1.3.1 Prostate-specific antigen
Prostate-specific antigen (PSA) testing, has been used as a screening and monitoring
method since 1980s [9]. PSA, a chymotrypsin-like protease, belonging to the family
of serine protease, only exists in the cytoplasm of prostatic acinus and ductal
epithelial cells and is overexpressed in the serum of patients with prostate cancer [10].
The higher PSA value, the greater the possibility of having prostate cancer. However,
PSA is not a tumor-specific indicator. PSA value could be affected by a variety of
factors including age and prostate volume, etc. [11]. Some other non-neoplastic
diseases, even medical approaches, which traumatically interfere with the structure
and function of the prostate, for instance, BPH, prostatitis, urine retention as well as
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catheterisation, could also make the concentration of PSA go up. Accordingly, PSA
level exceeding threshold doesn’t signify it is certainly a prostate malignancy and
influencing factors above should be also taken into consideration. Notably, while
prostate cancer mortality rate is declining with the routine use of PSA screening, this
PSA-based testing strategy increases risks of unnecessary prostate biopsy and
overtreatment of prostate cancer [12, 13]. United States Preventive Services Task
Force (USPSTF) once opposed PSA screening being used for all healthy crowed
without any hazards of prostate cancer. Benefits and potential harms of PSA
determination need to be discussed with every patient. American Urological
Association (AUA) guidelines specify that men ages from 55 to 69 years old might be
the optimal population to proceed PSA screening with greatest benefits [14].
1.3.2 Digital rectal examination
Together with PSA testing, digital rectal examination (DRE) is another recognised test
which could improve the early detection rate of prostate cancer. Jones and colleagues
[15] reported that the sensitivity and specificity of DRE in detection of prostate cancer
for symptomatic patients was 28.6 and 90.7%, respectively. DRE for the detection of
prostate cancer is also positively correlated with PSA level [16]. Prostate cancer with
Gleason score greater than 7 is more likely to be found in patients with suspicious
DRE [17]. DRE is more useful for detecting prostate cancer in peripheral zone, but it
is less powerful and effective for detecting tumors in transitional zone and central
zone because of the limitation of palpation distance, especially in patients with very
big prostate. Thereby, DRE is a relatively subjective measure which could be easily
influenced by experience and manipulative skills of clinicians.
1.3.3 Transrectal ultrasound
Typical prostate cancer appearing in transrectal ultrasound (TRUS) is characterised by
hypoechoic nodule [18], but there are still some prostate cancers verified in the
specimens of radical prostatectomy which are visualised as isoechoic (39%) and
hyperechoic (1%) lesions [19]. Sensitivity and specificity of TRUS for the detection
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of prostate cancer are also somewhat low and unsatisfying [20]. Currently, TRUS
modality is more set to guide prostate biopsy. The procedure of transrectal
ultrasound-guided prostate biopsy will be described in detail in the section of Material
and Methods.
1.3.4 Multiparametric magnetic resonance imaging (mpMRI)
In recent years, with the rapid development of imaging technologies, multiparametric
magnetic resonance imaging (mpMRI) was involved in the diagnosis and treatment of
prostate cancer. mpMRI is an imaging modality, employing not only conventional
T1-weighted imaging (T1WI) and T2-weighted imaging (T2WI) but also some
functional sequences mainly containing diffusion-weighted imaging (DWI) and
dynamic contrast-enhanced (DCE). DWI is the predominant reference sequence for
PZ tumor, while T2WI is applied as the primary distinguishing technique for TZ
tumor [21]. DCE findings which illustrate early and focal enhancement in malignant
lesions are also instructive and meaningful, offering considerable additional
diagnostic messages when interpreting and analysing with the results of T2WI and
DWI sequences. Prostate Imaging-Reporting and Data System (PI-RADS), an
assessment system of 5-point scale ranging from score 1 to score 5 based on the
likelihood of developing clinically significant prostate cancer (Figure 3), is introduced
and widely accepted to standardise mpMRI interpretation and reporting as well as to
eliminate disaccord and misreading between radiologists and urologists. 36 sections
for prostate, two for seminal vesicles and one for urethra should be assessed and
reported separately in mpMRI report (Figure 4).
Figrue 3. 5-point assessment scale in PI-RADS v2 (source from Moore CM et al [22] )
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Figure 4. Sector map in PI-RADS v2 (source from Weinreb JC, et al [21])
Several studies have highlighted that mpMRI is able to help define the clinically
significant prostate cancer and scrap unnecessary prostate biopsy, in particularly, for
patients with PSA level between 4 and 10 ng/ml [23-25]. mpMRI appears to perform
pretty high sensitivity (0.85) and pooled specificity (0.71) for the detection of prostate
cancer [26]. Furthermore, when changes on mpMRI are integrated into the follow-up
regime of active surveillance (AS) for cases with localised prostate cancer,
pathological progression rate would not rise compared with re-biopsy follow-up
strategies [27, 28]. mpMRI used to be the most cutting-edge imaging means of
detecting abnormality to select appropriate patients for further biopsy, but now is
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becoming a new measure to locate and illustrate lesions during targeted prostate
biopsy, which will be introduced in detail later on.
1.3.5 Overview of prostate biopsy and precision medicine
1.3.5.1 Systematic biopsy (SB)
It is truth universally acknowledged that pathological results are the gold standard for
diagnosis of tumor. Of course, to diagnose prostate cancer is no exception. The
indications of prostate biopsy depend on elevated PSA level, abnormal DRE findings,
questionable lesions on TRUS and suspected imaging on mpMRI. Prostate biopsy is
often performed via either transperineal access or transrectal access. There is no
significant difference between this two approaches over the detection rate of prostate
cancer [29, 30]. However, compared with transperineal procedure, transrectal protocol
owns several outstanding merits: less painful, no need to undergo spinal and general
anesthesia for patients as well as easy to master for clinicians [31, 32]. With regards to
potential complications, except rectum bleeding, the risk of fever, urethral bleeding
and urine retention in transrectal approach is also equivalent to it in transperineal way.
Thus, transrectal procedure is more fashionable and convenient (Figure 5).
Figure 5. Diagram of transrectal prostate biopsy approach (source from Guo LH et al [33])
As mentioned previously prostate cancer possessing the characteristics of multifocal
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growth and significant heterogeneity at various levels from genomic alterations to
morphological, spatial, and clinical diversity, so multi-core sampling strategy should
be utilised in prostate biopsy [5]. At present, 12-core systematic biopsy which
schematically samples the medial and lateral areas of three planes from apex to base
in both left side and right side of prostate is strongly recommended (Figure 6).
Figure 6. Diagram of 12-core systematic biopsy (source from You MW, et al [34])
1.3.5.2 Precision medicine and deficiency of systematic biopsy
The concept of precision medicine is that health care is tailored to individuals [35].
Briefly speaking, as US former president Obama said, precision medicine conveys
right medical decisions to the right patients in right time instead of delivering
universal standards of either diagnosis or treatment to every patient. As a result,
modern medicine is becoming more precise and personal. During my doctoral study, I
have advanced some new reflections and ideas concerning the application of liquid
biopsy for patients with renal cancer, which has been published in the platinum
journal, European Urology, and also concentrated on the feasibility of
non-whole-gland HIFU, as a type of focal therapy including hemiablation and zonal
ablation, for management of localised prostate cancer, which have been submitted to
Journal of Endourology and now is in the status of major revision. Both of them are
the embodiment of precision medicine and individual medicine (Appendix 1, 2). As
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mentioned above, it is the standard procedure that 12 cores are taken from the prostate
when conducting a transrectal systematic biopsy in the diagnostic pathway of prostate
cancer. This fashion is apparently a randomised, non-targeted, and imprecise approach.
Additionally, it is difficult for the needle of systematic biopsy to arrive at the apex and
anterior part of the prostate resulted from the restriction of puncture angle as well as
the volume of prostate. This leads to some apex tumors to be easily missed in
systematic biopsy path. The drawbacks of systematic biopsy can be inferred from the
diagram of this procedure (Figure 5). The detection rate of prostate cancer could
increase by 9.3% if additional dorsal apex is examined during the procedure of
systematic biopsy [36]. Likewise, in addition to apex and anterior areas, lesions
located in midline and extreme base are also easily to be missed and undersampled in
12-core systematic biopsy [37]. Another bias which cannot be ignored is that there
may be a slight difference among operators for sampling the same area. What is more
worthy mentioning is that systematic biopsy might detect more indolent and clinically
insignificant prostate cancers which is not supposed to be radically treated and is
associated with overdiagnosis and overtreatment [38, 39].
1.3.5.3 MRI/TRUS fusion targeted biopsy (TB)
With mpMRI integrated into biopsy protocol, mpMRI/TRUS fusion targeted biopsy is
becoming appealing and available. mpMRI makes identification of prostate cancer
precise rather than blind and aimless. MRI/TRUS fusion targeted biopsy is a new
method that uses software to fuse the preoperative mpMRI imaging with real-time
transrectal ultrasound to target related lesions and areas for patients who have
suspected mpMRI imaging. The specific protocol of MRI/TRUS fusion targeted
biopsy will be further elaborated in the part of Material and Methods. MRI/TRUS
fusion targeted biopsy has shown very good prospects in several trials. Prostate MRI
Imaging Study [40], also called PROMIS, a multicentric, paired-cohort, prospective
study, took template prostate mapping biopsy as reference and compared underlying
mpMRI-based biopsy strategy with transrectal systematic biopsy strategy, finding that
mpMRI-based targeted biopsy appeared to be more sensitive (93% vs 48%), but less
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specific (41% vs 96%) for detecting clinically significant prostate cancer (csPCa).
Based on this, 27% of patients could be avoided to undergo prostate biopsy and 5% of
clinically insignificant prostate cancers would be ruled out if using mpMRI as triage
test among biopsy-naive patients. Moreover, MRI/TRUS fusion targeted biopsy
pathway has been demonstrated to have higher detection rate of clinically significant
prostate cancer than systematic biopsy in patients undergone repeated biopsy after
previous negative biopsy, and over 38.9% of pathological upgrading were also
observed in MRI/TRUS fusion targeted biopsy in contrast with systematic biopsy [41].
Therefore, MRI/TRUS fusion targeted biopsy is a reliable method and sounds like the
ideal fashion for diagnosis of prostate cancer.
1.4 Controversies over biopsy strategies in patients with positive mpMRI
results
Obviously, patients with negative results on preoperative mpMRI, but continually
under suspicion of prostate cancer would undergo systematic biopsy. However, if the
patients are suspected with concerning lesions on mpMRI, the strategy of using
mpMRI fusion targeted biopsy will arouse some disputes on whether a concurrent
systematic biopsy should be performed in the same session. A very enthralling
randomised clinical trial, PRECISION [42] presented in EAU early this year, provides
the evidence that only performing MRI/TRUS fusion targeted biopsy has great
superiority for detecting clinically significant prostate cancer, indicating that patients
with positive mpMRI results could only undergo MRI/TRUS fusion targeted biopsy.
Another randomised clinical trial, omitting systematic biopsy and only conducting
MRI/TRUS fusion targeted biopsy achieves 50.5% of detection rate of overall
prostate cancer and 43.9% of detection rate of clinically significant prostate cancer
versus 29.5% and 18.1% in standard pathway based on systematic biopsy,
respectively [43]. Besides, psychological burden of patients cannot be neglected when
adding a 12-core systematic biopsy in MRI-based diagnostic strategy. A significant
number of patients with positive lesions on mpMRI who come to our clinic are always
afraid of the number of needle cores to be taken from prostate and the potential severe
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post-biopsy complications, and wondering whether they could only undergo
MRI/TRUS fusion targeted biopsy, but without missing any malignancies, at least
under the same diagnostic potency. Hence, MRI/TRUS fusion targeted biopsy alone
scheme will be an ideal method if it could embrace as comparable the cancer
detection rate as MRI/TRUS fusion targeted biopsy with systematic biopsy. However,
other studies suggest that the efficiency of MRI/TRUS fusion targeted biopsy has
been overestimated and it does not increase the detection rate of both overall prostate
cancer and clinically significant prostate cancer [44, 45]. In addition, it is remarkable
that MRI/TRUS fusion targeted biopsy also has defect to reach apex lesions,
especially in dorsolateral region, and even more than 16% of clinically significant
prostate cancers will be missed in MRI/TRUS fusion targeted biopsy. Surprisingly,
80% of cribriform cancers (Gleason pattern 4) are not identifiable in MRI/TRUS
fusion targeted biopsy fashion [46-48]. They assert that MRI/TRUS fusion targeted
biopsy cannot shake and replace systematic biopsy in the diagnosis of prostate cancer
for patients with positive mpMRI results and incorporating with systematic biopsy
could yield better outcomes than only performing MRI/TRUS fusion targeted biopsy
[49]. This is the reason why most urologists are still conservative and adopt
MRI/TRUS fusion targeted biopsy together with 12-core systematic biopsy in patients
with positive results on mpMRI, so is our department.
1.5 Scientific questions of the study
In summary, the biopsy strategies for patients with positive mpMRI results are still
unclear and controversial. Is MRI-based diagnostic pathway really superior to
standard pathway in the aspect of oncological outcomes and complications? Can we
omit the systematic biopsy for patients with positive mpMRI results? If it is not
applicable in all cases, is it possible to only carry out MRI/TRUS fusion targeted
biopsy for special cases from the point of view of mpMRI parameters of lesions?
What influence factors are together contributing to the detection rate of clinically
significant prostate cancer in MRI/TRUS fusion targeted biopsy approach or
MRI/TRUS fusion targeted biopsy combined with systematic biopsy approach? How
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to balance the detection rate of clinically significant prostate cancer and the detective
risk of clinically insignificant prostate cancer for those patients?
1.6 Objectives and framework of the study
Based on the current clinical strategy of prostate biopsy, to evaluate the possibility of
omitting systematic biopsy and verify whether only performing MRI/TRUS fusion
targeted biopsy is sufficient for the diagnosis of prostate cancer in particular cases
with positive mpMRI results, I propose to: (1) analyse the techniques itself of both
MRI/TRUS fusion targeted biopsy and systematic biopsy; (2) explore the oncological
efficacy and agreement, as well as complications of patients between MRI-based
biopsy pathway (MRI/TRUS fusion targeted biopsy plus systematic biopsy) and
standard biopsy pathway (systematic biopsy only) in order to verify the effectiveness
and safety of MRI-based biopsy strategy; (3) identify the relative contributions of
MRI/TRUS fusion targeted biopsy alone (TB), systematic biopsy alone (SB) and
combined scheme (TB+SB) for the detection of prostate cancer as well as clinically
significant prostate cancer in all patients who underwent MRI/TRUS fusion targeted
biopsy combined with 12-core systematic biopsy; (4) assess the relevancy between
MRI parameters and the detection rate of clinically significant prostate cancer in
MRI/TRUS fusion targeted biopsy alone scheme and combined scheme, relatively; (5)
establish multivariate logistic regression models for the purpose of determining all the
possible influence factors contributing to the detection of clinically significant
prostate cancer in MRI/TRUS fusion targeted biopsy alone approach and MRI/TRUS
fusion targeted biopsy along with systematic biopsy approach individually. In
summary, we hope to sketch out some rough criteria which might be the reference to
select suitable patients with suspicious lesions on mpMRI to undergo the MRI/TRUS
fusion targeted biopsy without additional 12-core systematic biopsy.
Material and Methods
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2 Material and Methods
2.1 Patients selection
A consecutive series of cases suspected with prostate cancer who underwent
prostate biopsy from January 2017 to March 2018 in our centre, Diakonie Klinikum
Stuttgart, were considered as targeted population in this retrospective study. Patients
without diagnosis of prostate cancer previously can be enrolled in this study. Patients
were excluded if they had evidence of metastases at diagnosis. All the participants at
least met one of the following indications of prostate biopsy: raised serum PSA level
(≥ 4ng/ml); abnormal digital rectal examination; imaging abnormality on either TRUS
or mpMRI. In total, 272 patients fulfilling the criteria above were recruited in this
retrospective study, of which 139 patients with positive mpMRI results underwent
MRI/TRUS fusion targeted biopsy followed by a 12-core systematic biopsy approach
(MRI group), and the rest of 133 patients without suspicious mpMRI scan only
underwent 12-core systematic biopsy approach (Standard group). In addition to
mpMRI-related outcomes in MRI group, serum PSA value, prostate volume, PSA
density (PSAD), family history of prostate cancer and prior negative biopsy status
were also assessed as basic demographics in both MRI group and standard group. Of
note, prostate volume was calculated by ultrasound system automatically through
elliptic evaluation (diameter of height × diameter of width × diameter of length × 0.52)
in my study.
2.2 The procedure of systematic biopsy
All the patients had a physical examination, a blood testing as well as an urine testing,
and signed the informed consent prior to the prostate biopsy. Patients with blood
coagulation disorders, acute infectious disease, etc. were not the suitable candidates
for prostate biopsy. Oral antibiotic prophylaxis (ciprofloxacin 500mg) and a certain
extent of bowel preparation one day before the prostate biopsy are helpful and
necessary for patients. At the beginning of the procedure, the patient was placed in the
left lateral position and the digital rectal examination was performed to evaluate the
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tone of rectum and the texture of prostate as well as relax the anal sphincter slightly.
After ultrasound probe was inserted into the rectum, we could get access to the
prostatic ultrasonic imaging and measure the volume of prostate as well. After that,
under periprostatic local anesthesia with 10ml scandicaine, a reusable biopsy gun with
18-gauge spring-driven needle (Bard, Arizona, USA) was used to perform the biopsy.
The whole procedure was guided and monitored by real-time transrectal ultrasound
with the imaging of both sagittal and axial plane of the prostate. 12 cores were
obtained according to the standard scheme which has been depicted in Figure 6.
Prostate biopsy cores from different areas were separately labeled and fixed with
formalin solutions in small containers, and then embedded with paraffin. Once more
digital rectal examination would also be routinely performed after the whole
procedure. Oral antibiotic ciprofloxacin needed to be taken for another three days in
our protocol.
2.3 Multiparametric Magnetic Resonance Imaging
mpMRI was performed mostly with 3Tesla scanner without using endorectal coils
(Siemens, Erlangen, Germany), only eight patients was scanned with 1.5 Tesla MRI.
T1-weighted imaging (T1WI), T2-weighted imaging (T2WI), diffusion-weighted
imaging (DWI), dynamic contrast-enhanced (DCE) sequences were normally
interpreted and reported compliant with Prostate Imaging-Reporting and Data System
(PI-RADS) guideline in each patient who underwent mpMRI scan. The mpMRI
imaging was interpreted by three experienced senior attending radiologists (Oberarzt)
who have been engaged in MRI diagnosis of prostate cancer for at least four years.
The suspicious regions of interest (ROIs) were marked and assigned with PI-RADS
score individually by radiologists.
2.4 The procedure of MRI/TRUS fusion targeted biopsy
MRI/TRUS fusion targeted biopsy was performed with software registration method
(Hi-RVS/Hitachi, Tokyo, Japan). The lesions scored of PI-RADS 3, 4, or 5 would be
carried out with MRI/TRUS fusion targeted biopsy. Preoperative preparation, posture,
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and anesthesia of patients were the same with 12-core systematic biopsy. After
mpMRI imaging was imported into ultrasound machine, anatomical landmarks
including lower margin of pubic bone and membranous urethra could be used to help
urologists overlap the imaging of preoperative mpMRI imaging with the imaging of
real-time TRUS. Typically, at least two cores would be taken from each suspicious
ROI contoured by radiologists on preoperative mpMRI imaging, except seven ROIs
sampled with only one needle core. MRI/TRUS fusion targeted biopsy was prior to
12-core systematic biopsy in all patients with positive mpMRI results.
2.5 Pathology
Prostate specimens were reviewed by dedicated pathologists in the same clinic. Each
core was reported dividedly and had its own diagnosis in the pathological report.
General assessment including gross length of single core and its location, as well as
microscopic examination were performed in each patient. When it comes to the
diagnosis of prostate cancer, some precancerous pathological lesions containing high
grade prostatic intraepithelial neoplasia (HGPIN) and atypical small acinar
proliferation (ASAP) involved in the core should also be described if we cannot
entirely diagnose it as benign tissue. In addition to pathological type, Gleason score
(GS) consisting of primary and secondary Gleason grade, Gleason group based on
ISUP 2014 consensus, and the number of positive core as well as cancer involvement
per core needed to be recorded in tumor patients. In the current study, clinically
significant prostate cancer (csPCa) was defined using the following three criteria:
PROMIS criterion (GS ≥ 4+3 or maximum cancer core length (CCL) ≥ 6 mm) [40];
START criterion (GS ≥7 or cancer core length (CCL) ≥5 for GS =6) [22]; PI-RADS
criterion (GS ≥ 7) [21, 50]. The definition of clinically insignificant cancer is GS = 6
or ISUP =1.
2.6 Outcomes assessment
2.6.1 Oncological outcomes
The detection rate of prostate cancer and the detection rate of clinically significant
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prostate cancer were calculated in this study. Based on this, diagnostic efficiency and
consistency were mainly assessed to compare different prostate biopsy strategies for
diagnosis of prostate cancer. Moreover, MRI parameters involved in the detection of
prostate biopsy would also be evaluated individually in this study. Furthermore, all the
predictors related to the detection rate of clinically significant prostate cancer in each
prostate biopsy approach were also identified in the analysis.
2.6.2 Complications
All the patients were observed for underlying biopsy-related complications including
macrohematuria, urinary tract infection, fieber, urine retention and vasovagal reaction.
For macrohematuria, we did not count transient mild hematuria, only one time after
biopsy procedure, as macrohematuria. Patients were told that they did not necessarily
come to ambulance if hematuria was just one time without other symptoms after
prostate biopsy. Analyses on complications were carried out for patients in both MRI
group and standard group.
2.7 Statistical analysis
The mean differences of continuous variables between three groups or between
different biopsy schemes were compared using One-way ANOVA in current study.
T-test was performed to assess the difference of continuous variables between two
groups, while Chi-square or Fisher exact test was used for comparison of proportions
of categorical variables between two groups. In addition, we fitted two binary logistic
regresssion models with the thresholds of αentry=0.05 and αremoval=0.1 to evaluate the
correlation between potential risk factors and the detection rate of clinically
significant prostate cancer respectively in different biopsy strategies. All data were
analysed using SPSS software 21.0. p value no more than 0.05 was considered
statistically significant.
Results
17
3 Results
3.1 The length of single core in systematic biopsy
From January 2017 to March 2018, a total of 272 patients undergone prostate biopsy
in Diakonie Klinikum Stuttgart fulfilling the inclusive criteria were enlisted in this
research. MRI/TRUS fusion targeted biopsy followed by systematic biopsy was used
in 139 patients with suspicious areas on mpMRI and systematic biopsy alone was
applied in 133 cases without positive mpMRI results. We first analysed the biopsy
technique itself from the perspective of the length of single core taken from the
prostate for the purpose of optimising the biopsy strategy, for Iczkowski and his
colleagues have addressed the length of single core sampled by biopsy played an
important role on the detection of prostate cancer [51]. Figure 6 and Figure 7
exhibited the length of single core for systematic biopsy in standard group and the
average length of four cores in apex, middle and base level for systematic biopsy in
standard group, respectively. Apart from the needle core of right apex, there was no
statistically significant difference in the length of single core between the other 11
cores (p=0.089). In addition, we found a very interesting phenomena that the length of
apex core was shorter than the length of middle or the length of base core no matter in
medial or lateral line on both lobes, though its difference was not statistically
significant. The average length of four apex cores including right apex, right apex
lateral, left apex and left apex lateral was obviously shorter than that in the middle
plane (p=0.000) or that in the base plane (p=0.001). Nevertheless, the average length
of cores in the middle level was comparable to that in the base level (p=0.068).
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Figure 7. Gross length of each core for systematic biopsy in standard group. Ⅰ: right apex; Ⅱ:
right middle; Ⅲ: right base; Ⅳ: right apex lateral; Ⅴ: right middle lateral; Ⅵ: right base lateral;
Ⅶ: left apex;Ⅷ: left middle; Ⅸ: left base; Ⅹ: left apex lateral; Ⅺ: left middle lateral; Ⅻ: left
base lateral. Ⅰ to Ⅲ represent cores taken from the right medial line andⅦ to Ⅸ are the cores
sampled from the left medial line.
Figure 8. Average length of cores in three planes of prostate in standard group
We further expanded the sample size to all patients who underwent the systematic
biopsy in both MRI group and standard group, and the results were the same as the
analyses concerning only the patients from the standard group. The length of single
core in right apex, right apex lateral or left apex lateral was markedly below the length
of single core in any other nine sites, and the length of these nine cores was similar to
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each other (p=0.086) (Figure 8). Equally, the average length of either the middle cores
(p=0.000) or the base cores (p=0.000) was longer than the length of the apex cores,
but no statistical differences were shown between the average length of middle cores
and the base cores (p=0.675) (Figure 9).
Figure 9. Gross length of each core for systematic biopsy in all patients. Ⅰ: right apex; Ⅱ: right
middle; Ⅲ: right base; Ⅳ: right apex lateral; Ⅴ: right middle lateral; Ⅵ: right base lateral; Ⅶ: left
apex; Ⅷ: left middle; Ⅸ: left base; Ⅹ: left apex lateral; Ⅺ: left middle lateral; Ⅻ: left base
lateral. Ⅰ to Ⅲ represent cores taken from the right medial line andⅦ to Ⅸ are the cores sampled
from the left medial line.
Figure 10. Average length of cores in three planes of prostate in all patients
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3.2 Baseline characteristics, oncological outcomes and complications of
patients
3.2.1 Baseline characteristics
The demographics of patients in MRI group and standard group were listed in Table 1.
Age at biopsy (p=0.052), PSA (p=0.919), prostate volume (p=466), PSAD (p=0.490),
family history of prostate cancer (p=0.768) and digital rectal examination (p=0.489)
did not differ between MRI group and standard group. However, more patients in
MRI group seem to have previously experienced a negative biopsy than patients in
standard group (27.3% versus 17.3%; p=0.047).
Table 1. Baseline characteristics for patients in MRI group and standard group
Variables Standard group MRI group p value
Number 133 139
Age at biopsy (year) 69.62±8.01 67.76±7.73 0.052
PSA (ng/ml) 10.24±9.90 10.12±9.23 0.919
Prostate volume (ml) 51.38±23.78 53.62±26.57 0.466
PSA density 0.23±0.23 0.22±0.20 0.490
Family history of prostate cancer (%) 0.768
Yes 3 (2.3) 5 (3.6)
No 130 (97.7) 134 (96.4)
Digital rectal examination (%) 0.489
Suspect 62 (46.6) 59 (42.4)
Normal 71 (53.4) 80 (57.6)
Prior negative biopsy (%) 0.047
Yes 23 (17.3) 38 (27.3)
No 110 (82.7) 101 (72.7)
3.2.2 Oncological outcomes
The oncological outcomes were summarised in Table 2. The detection rates of benign
tissue, atypical small acinar proliferation (ASAP), high grade prostatic intraepithelial
neoplasia (HGPIN) and malignancy were comparable between this two groups
(p=0.294), with 36.8%, 3.8%, 4.5% and 54.9% of 133 patients belonging to the
standard group, respectively and 27.9%, 2.1%, 4.3% and 65.7% of 139 cases in the
MRI group, respectively. It was in line with the paralleled findings of detection rate of
overall prostate cancer between this two groups (54.9% versus 66.2%; p=0.057). Of
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them, only one patient in MRI group presented both precancerous lesion ASAP and
precancerous lesion HGPIN. Detected prostate cancers classified by Gleason score
were also comparable between these two groups (p=0.145). The detection rate of
clinically significant prostate cancer identified in MRI group based on PROMIS
criterion (p=0.043) or START criterion (p=0.038) was apparently higher than it
recorded in standard group, though no statistical difference was found between these
two groups according to PI-RADS criterion (p=0.084). In terms of clinically
insignificant prostate cancer, 14.4% of clinically insignificant prostate cancers were
reported in MRI group, which was similar to 13.5% of it in standard group. Other
pathological factors like the number of positive cores per patient and the total number
of cores per patient in MRI group were certainly more than that in standard group due
to more cores sampled in MRI group (p=0.022; p=0.000). Nevertheless, the average
length of cores in MRI group was shorter than it in standard group (p=0.000). No
significant differences were found regarding total cores positive for cancer (p=0.327)
and maximum length of cancer core (p=0.335) when comparing these two groups.
Accordingly, MRI/TRUS fusion targeted biopsy together with systematic biopsy
could achieve excellent oncological results for patients in MRI group.
Table 2. Oncological outcomes for patients in MRI group and standard group
Variables Standard group MRI group p value
Prostate biopsy outcome (%) 0.294
Benign tissue 49 (36.8) 39 (27.9)
ASAP 5 (3.8) 3 (2.1)
HGPIN 6 (4.5) 6 (4.3)
Malignancy 73 (54.9) 92 (65.7)
Gleason score (%) 0.145
3+3 (ISUP1) 18 (24.7) 20 (21.7)
3+4 (ISUP2) 17 (23.3) 21 (22.8)
4+3 (ISUP3) 8 (11.0) 23 (25.0)
8 (ISUP 4) 12 (16.4) 15 (16.3)
> 8 (ISUP 5) 18 (24.7) 13 (14.1)
Total cancer detection (%) 73 (54.9%) 92 (66.2) 0.057
Clinically significant cancer#1 (%) 48 (36.1) 67 (48.2) 0.043
Clinically significant cancer#2 (%) 56 (42.1) 76 (54.7) 0.038
Clinically significant cancer#3 (%) 55 (41.4) 72 (51.8) 0.084
Clinically insignificant cancer* (%) 18 (13.5) 20 (14.4) 0.839
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Average length of core (mm) 15.26±2.17 14.30±2.05 0.000
Maximum length of cancer core (mm) 8.17±6.69 7.26±4.97 0.335
Number of positive cores per patient 2.59±3.53 3.68±4.22 0.022
Total number of cores per patient 12.19±0.85 16.29±1.93 0.000
Total core positive for cancer (%) 344/1621 (21.2) 511/2267(22.5) 0.327
#1PROMIS criterion (GS ≥ 4+3 or maximum cancer core length (CCL) ≥ 6 mm); #2START criterion (GS ≥7 or cancaer core length (CCL)
≥5 for GS =6); #3PI-RADS criterion (GS ≥7); *Criteria (GS =6)
3.2.3 Complications of patients
Adding systematic biopsy in MRI group actually did not increase the total incidence
of complications compared to standard group (p=0.431). Complications in MRI group
and standard group were reported in Table 3. Macrohematuria was the most common
complication in standard group, while urinary tract infection occurred mostly in MRI
group. Besides, macrohematuria and fever were observed simultaneously in one case
in each group. There was also one patient combining urinary tract infection with fever
in both groups. One patient developed an acute epididymitis in standard group
because of severe urinary tract infection. It must be noticed that vasovagal reaction
occurred in two cases in standard group and one case in MRI group, even vasovagal
syncope appearing in one case during the biopsy procedure, but all of them recovered
after urologist stopped operating and carried out cardio-pulmonary resuscitation
(CPR). Thus, the complications for the strategy of MRI/TRUS fusion targeted biopsy
followed by systematic biopsy were acceptable compared with standard biopsy
strategy.
Table 3. Complications of patients in MRI group and standard group
Variables Standard group MRI group p value
Number of complications (%) 12 (9.0) 9 (6.5) 0.431
Macrohematuria 4 1
Urinary tract infection 3 3
Fever 2 2
Urine retention 1 2
Vasovagal reaction 2 1
3.3 Efficiency of TB, SB, and TB+SB scheme for patients in MRI group
Among 139 patients with positive mpMRI results who were initiated on MRI/TRUS
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fusion targeted biopsy followed by systematic biopsy, a separate analysis was
conducted over the contribution of targeted biopsy alone (TB), systematic biopsy
alone (SB) and targeted biopsy plus systematic biopsy (TB+SB) to the detection of
prostate cancer, respectively. All the data were presented in Table 4. For the detection
rate of overall prostate cancer, TB combined with SB was superior to TB alone or SB
alone scheme (p=0.050). The detection rate of clinically significant prostate cancer
was not statistically distinguishable among these three schemes based on three
different criteria of clinically significant prostate cancer in my study, though TB+SB
scheme is generally held to be able to detect more clinically significant prostate
cancers than TB alone or SB alone scheme. It at least hints that besides the small
elevated section of clinically significant prostate cancer, an increase in the detection
of overall prostate cancer in the scheme of TB plus SB might be resulted from the
detection of a large number of clinically insignificant prostate cancers.
Interestingly, the discrimination of clinically insignificant prostate cancer among these
three schemes were observed neither between TB and TB+SB nor SB and TB+SB,
only between TB alone and SB alone. It indicates that SB scheme was more likely to
discover clinically insignificant tumor which was indolent, undesired and less
progressive compared with TB alone scheme (16.5% versus 6.5%), yet statistically,
the union of TB and SB would not enhance the detection rate of clinically
insignificant prostate cancer in comparison with TB alone or SB alone scheme in the
study. In addition, no statistical difference was shown with respect to the maximum
length of cancer core between these three schemes (p=0.080), whereas TB combined
with SB could obtain more positive cores in patients with prostate cancer than SB
alone or TB alone scheme (3.68 versus 2.40 versus 1.27; p=0.000). Furthermore, TB
alone scheme could achieve a relatively longer average length of core than SB alone
or TB incorporated with SB procedure (15.78mm versus 14.10mm versus 14.29mm;
p=0.000), with the advantage of fewer cores taken from the prostate (4.31 versus
12.00 versus 16.31; p=0.000). In TB alone scheme, it also displayed higher detective
efficiency (29.5%), with 177 positive cores taken from gross 599 cores, than SB alone
scheme (20.0%), with 334 positive cores obtained from total 1668 cores or TB
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consolidated with SB scheme (22.5%), with 511 positive cores sampled from overall
2267 cores. Hence, TB alone scheme might be regarded as an alternative way to TB
plus SB scheme in patients with positive mpMRI results according to the oncological
efficacy.
Table 4. Oncological efficacy of three schemes for patients in MRI group
Variables SB alone TB alone TB+SB p value
Number 139 139 139
Prostate biopsy outcome (%) 0.047
Benign tissue 47 (33.1) 63 (45.3) 39 (27.9)
ASAP 5 (3.5) 1 (0.7) 3 (2.1)
HGPIN 7 (4.9) 3 (2.2) 6 (4.3)
Malignancy 83 (58.5) 72 (51.8) 92 (65.7)
Gleason socre (%) 0.469
3+3 (ISUP1) 23 (27.7) 9 (12.5) 20 (21.7)
3+4 (ISUP2) 15 (18.1) 22 (30.6) 21 (22.8)
4+3 (ISUP3) 19 (22.9) 21 (29.2) 23 (25.0)
8 (ISUP 4) 14 (16.9) 11 (15.3) 15 (16.3)
> 8 (ISUP 5) 12 (14.5) 9 (12.5) 13 (14.1)
Total cancer detection (%) 83 (59.7) 72 (51.8) 92 (66.2) 0.050
Clinically significant cancer#1
(%)
55 (39.6) 57 (41.0) 66 (47.5) 0.364
Clinically significant cancer#2
(%)
68 (49.6) 67 (48.2) 84 (60.4) 0.083
Clinically significant cancer#3
(%)
60 (43.2) 63 (45.3) 72 (51.8) 0.324
Clinically insignificant cancer*
(%)
23 (16.5) 9 (6.5) 20 (14.4) 0.028
Average length of core (mm) 14.10±2.17 15.78±3.62 14.29±2.06 0.000
Maximum length of cancer
core (mm)
3.58±5.01 3.60±4.61 4.80±5.30 0.080
Number of positive cores per
patient
2.40±3.10 1.27±1.54 3.68±4.22 0.000
Total number of cores per
patient
12.00±0.00 4.31±2.00 16.31±2.00 0.000
Total core positive for cancer
(%)
334/1668 (20.0) 177/599 (29.5)
511/2267
(22.5)
0.000
#1PROMIS criterion (GS ≥ 4+3 or maximum cancer core length (CCL) ≥ 6 mm); #2START criterion (GS ≥7 or cancaer core length (CCL)
≥5 for GS =6); #3PI-RADS criterion (GS ≥7); *Criteria (GS =6).
3.4 Consistency of TB and TB+SB scheme for patients in MRI group
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Cancer detection and distribution of Gleason score in TB scheme as well as TB plus
SB scheme were listed in Table 5. It can be clearly seen that 20 patients identified
with prostate cancer in TB plus SB scheme would be missed using only TB scheme,
of which nine cases were encountered with clinically significant prostate cancer
(Table 6). Among 92 patients with prostate cancer found by TB scheme, six patients
with GS 7a, seven patients with GS 7b and three patients with GS 8 were examined to
have an upgraded GS after the addition of SB scheme. However, if the patients have
been demonstrated with clinically insignificant prostate cancer in TB scheme,
additional SB scheme would not upgrade the GS for patients in the same session.
Consequently, when adding systematic biopsy after the MRI/TRUS fusion targeted
biopsy, the detection rate of clinically significant prostate cancer would increase by
6.5%, but as much as 7.9% risk of more clinically insignificant prostate cancers would
be diagnosed at the same time.
Table 5. Cancer yield and GS distribution between TB and TB+SB scheme for patients in
MRI group
TB scheme
TB+SB scheme
No cancer GS=6 GS=7a GS=7b GS=8 GS>8
No cancer 47 11 5 4 0 0
GS=6 0 9 0 0 0 0
GS=7a 0 0 16 5 0 1
GS=7b 0 0 0 14 6 1
GS=8 0 0 0 0 9 3
GS>8 0 0 0 0 0 8
Table 6. Cancer yield and categorisation by clinical significance between TB and TB+SB
scheme for patients in MRI group
TB scheme
TB+SB scheme
No cancer
Clinically
insignificant
Cancer*
Clinically
significant
cancer#
No cancer 47 11 9
Clinically insignificant cancer 0 9 0
Clinically significant cancer# 0 0 63
#PI-RADS criteria (GS ≥7); *Criteria (GS =6)
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3.5 The basic features of all the mpMRI suspicions in MRI group
Of all 139 patients in MRI group, a total of 212 lesions were found on preoperative
multiparametric magnetic resonance imaging (mpMRI), including 51 lesions scored
for PI-RADS 3, 118 lesions for PI-RADS 4, and 43 lesions for PI-RADS 5 (Table 7).
One suspicious region of interest (ROI) was visible in 87 patients and suspicious
ROIs ranging from two to four were identified in 34, 15 and 3 patients, respectively.
Four lesions were located in anterior fibromusclar zone and ten lesions were measured
in central zone. 133 and 65 lesions visualized on mpMRI were sorted to peripheral
zone and transitional zone, respectively.
Table 7. Lesions identified by mpMRI in MRI group
Variables Value
mpMRI PI-RADS score (%) 212
3 51 (24.0)
4 118 (55.7)
5 43 (20.3)
Number of ROI (%) 139
1 87 (62.6)
2 34 (24.5)
3 15 (10.8)
4 3 (2.1)
Location of MRI target (%) 212
AFS 4 (1.9)
CZ 10 (4.7)
TZ 65 (30.7)
PZ 133 (62.7)
AFS: anterior fibromusclar zone; CZ: central zone; TZ: transitional zone; PZ: peripheral zone.
3.6 Efficiency and consistency of TB and TB+SB scheme for all lesions in MRI
group
As displayed in Figure 11 and 12, we carried out a similar analysis over the detection
of prostate cancer using TB or TB plus SB scheme for all the 212 lesions on mpMRI
imaging. Gleason score upgrading was determined in 51 lesions implemented by TB
plus SB scheme in comparison with TB alone scheme, about a quarter of the total
suspicions on mpMRI (Table 8 and Table 9). TB followed by SB scheme could
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increase the detection rate of overall prostate cancer by 24.1% and the detection rate
of clinically significant prostate cancer by 12.7% compared to TB alone scheme.
However, as much as 11.3% of clinically insignificant prostate cancers were
overdiagnosed in TB plus SB scheme as well, which was not expected.
Figure 11. Cancer yield and GS distribution between the three schemes for all lesions in MRI
group
Figure 12. Tumor clinical significance detected between the three schemes for all lesions in
MRI group
Table 8. Cancer yield and GS distribution between TB and TB+SB scheme for all lesions in
MRI group
TB scheme
TB+SB scheme
No cancer GS=6 GS=7a GS=7b GS=8 GS>8
No cancer 73 24 12 6 5 2
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GS=6 0 9 1 0 1 0
GS=7a 0 0 19 8 1 2
GS=7b 0 0 0 15 8 2
GS=8 0 0 0 0 12 3
GS>8 0 0 0 0 0 9
Table 9. Cancer yield and categorisation by clinical significance between TB and TB+SB
scheme for all lesions in mpMRI group
TB scheme
TB+SB scheme
No cancer
Clinically
insignificant
Cancer*
Clinically
significant
cancer#
No cancer 73 24 25
Clinically insignificant cancer 0 9 2
Clinically significant cancer 0 0 79
#PI-RADS criteria (GS ≥7); *Criteria (GS =6)
3.7 Relevancy between mpMRI results and the detection of prostate cancer
As discussed above, TB plus SB scheme could definitely detect more prostate cancers,
in particular, clinically significant prostate cancers in the same session in MRI group
compared with TB alone scheme, but it also bears the risk of detecting considerable
numbers of clinically insignificant prostate cancer, which greatly discounts its
advantages. As for TB alone scheme, though it is powerful enough for the detection of
prostate cancer, it would still miss some cases harbouring clinically significant
prostate cancer. Helping to investigate whether in some certain cases TB could be
used as an alternative scheme to achieve the identical diagnostic efficiency without
missing any clinically significant prostate cancers compared with TB plus SB scheme,
we carried out a correlation analysis between mpMRI findings of lesions and the
detection of prostate cancer.
The pathological outcomes of patients with one suspicious ROI, two suspicious ROIs,
and three or more suspicious ROIs in TB alone scheme and TB plus SB scheme were
graphed in Figure 13 and Figure 14. The distribution of Gleason score and detection
rate of clinically significant prostate cancer as well as clinically insignificant prostate
cancer between TB and TB plus SB scheme were not different from each other no
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matter how many ROIs a patient had. It illustrates that the number of ROIs per patient
does not appear to be a major affecting factor in picking the optimal biopsy strategy
for patients with positive mpMRI results.
Figure 13. Pathological outcomes classified by the number of ROIs between TB and TB+SB
scheme for patients in MRI group
Figure 14. Tumor clinical significance detected in TB and TB+SB scheme in subgroups of
number of ROIs for patients in MRI group
Next, an association analysis was made between PI-RADS score of lesions on
mpMRI and the detection of prostate cancer (Figure 15 and 16). In lesion with
PI-RADS score of 5, TB+SB scheme did not show statistical superiority in the
detection rate of overall prostate cancer and the detection rate of clinically significant
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prostate cancer compared to TB alone scheme, whilst it did not increase the detection
rate of clinically insignificant prostate cancer. Using this combined approach, 14.4%
(17 cases) more cases would be identified with clinically significant prostate cancer in
PI-RADS 4 subgroup, but 10.2% (12 cases) more patients with clinically insignificant
prostate cancer would also be confirmed at the same time. For 51 lesions with
PI-RADS score of 3, the detection rate of clinically significant prostate cancer was
similar between TB alone and TB plus SB scheme. However, additional systematic
biopsy following targeted biopsy could increase the detection rate of clinically
insignificant prostate cancer by 13.8% (7 cases) compared with TB alone scheme.
Therefore, TB alone scheme has proved pretty good diagnostic efficiency for lesions
with PI-RADS 3. To sum it up, when only PI-RADS score was taken into
consideration, TB alone scheme could be simply performed for patients with
PI-RADS score of 3 and 5, but for patients with PI-RADS score of 4, the selection of
biopsy scheme depends on the individual case.
Figure 15. Pathological outcomes classified by PI-RADS score between TB and TB+SB
scheme for all lesions in MRI group
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Figure 16. Tumor clinical significance between TB and TB+SB scheme in subgroups of
PI-RADS score for all lesions in MRI group
Figure 17 and Figure 18 present the individual diagnostic efficiency of TB alone and
TB+SB scheme for lesions located in different prostate regions on mpMRI. For
lesions located in central zone or anterior fibromusclar zone, there was no significant
difference between TB alone and TB+SB scheme in the detection rate of overall
prostate cancer as well as the detection rate of clinically significant prostate cancer.
But we cannot genuinely conclude that TB over TB plus SB approach was
comparable in dealing with lesions in central zone or anterior fibromusclar zone due
to such a small sample size. Of 133 lesions in peripheral zone included in the analysis,
combined scheme could detect more prostate cancers than TB alone scheme, with
more cases (15 cases; 11.3%) with clinically significant prostate cancer and more
patients with clinically insignificant prostate cancer (10 cases; 7.5%) diagnosed,
despite that the detection rate of clinically significant prostate cancer and the detection
rate of clinically insignificant prostate cancer were not statistically significant
between the two schemes. Besides, results were also obtained for lesions in
transitional zone. Here clinically significant prostate cancer was found more often in
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TB+SB scheme than in TB alone scheme (32.3% versus 15.4%; p<0.05) as well as
clinically insignificant prostate cancer (18.5% versus 4.6%; p<0.05). In conclusion,
both TB alone scheme and TB plus SB scheme have their own advantages and
disadvantages for the detection of prostate cancer among lesions positioned in
peripheral zone or transitional zone. The more clinically significant prostate cancer
was detected, the more clinically insignificant prostate cancer would also be detected
in the same session. However, TB alone scheme seems to be powerful enough to use
for lesions in peripheral zone.
Figure 17. Pathological outcomes classified by location between TB and TB+SB scheme for
all lesions in mpMRI group. AFS: anterior fibromusclar zone; CZ: central zone; PZ: peripheral
zone; TZ: transitional zone.
Figure 18. Tumor clinical significance between TB and TB+SB scheme in subgroups of
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location for all lesions in mpMRI group. AFS: anterior fibromusclar zone; CZ: central zone; PZ:
peripheral zone; TZ: transitional zone.
Further, the influence of the diameter of lesion on the detection of prostate cancer was
estimated in both TB and TB+SB scheme as well (Figure 19 and Figure 20). The
lesions on mpMRI were divided into three groups based on their diameter: no more
than 10mm group, between 10mm and 20mm group, and no less than 20mm group. In
group of lesion diameter between 10mm and 20mm, the detection rate of prostate
cancer in TB+SB scheme did not differ from it in TB alone scheme from a statistical
point of view, with 53 of 76 lesions found in TB+SB scheme and 39 of 76 lesions
found in TB alone scheme. The detection rate of clinically significant prostate cancer
was also comparable between these two schemes, with 44 of 76 lesions verified in
TB+SB scheme and 33 of 76 lesions verified in TB alone scheme. When it comes to
the group of lesion diameter no more than 10mm, clinically insignificant prostate
cancer was found in 17 (15.6%) out of 109 lesions in combined scheme, while it was
found in 4 (3.7%) out of 109 lesions in TB alone scheme (p<0.05). Nevertheless, the
detection rate of clinically significant prostate cancer in TB+SB scheme would not be
higher than the one in TB alone approach. For lesion diameter no less than 20mm, TB
scheme was also not inferior to TB+SB approach concerning the detection rate of
clinically significant prostate cancer. On the contrary, TB scheme could reduce the
detection rate of clinically insignificant cancer compared to TB+SB scheme. In
summary, the lesion diameter as a predictor for the detection rate of prostate cancer as
well as clinically significant prostate cancer was not different between these two
schemes. Added SB approach after TB procedure would just improve the detection
rate of clinically insignificant prostate cancer instead of increasing the detection rate
of clinically significant prostate cancer when diameter of lesion was subjected to
analysis. Accordingly, the diameter of lesion was not a key factor in judging biopsy
strategy in patients with positive mpMRI results.
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Figure 19. Pathological outcomes classified by diameter of lesion between TB and TB+SB
scheme for all lesions in mpMRI group
Figure 20. Tumor clinical significance between TB and TB+SB scheme in subgroups of
diameter of lesion for all lesions in mpMRI group
3.8 Multivariate logistic regression model for TB and TB+SB scheme
Ultimately, we investigated the predictors for the detection of clinically significant
prostate cancer in TB alone and TB plus SB scheme respectively using multivariate
logistic regression analysis (Table 10 and Table 11). Out of mpMRI parameters, only
PI-RADS score and lesion location, which were different between TB alone scheme
and TB+SB scheme to the detection of clinically significant prostate cancer in
univariate analysis, were chosen for the multivariate logistic regression analysis. The
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multivariate logistic regression analysis showed that the age at biopsy, PSAD, family
history of prostate cancer, prior negative biopsy status, PI-RADS score, and the
location of lesion were the independent predictors for the detection rate of clinically
significant prostate cancer in TB alone scheme, whereas the age at biopsy, PSAD,
digital rectal examination, prior negative biopsy status, PI-RADS score, and the
location of lesion were independently associated with the detection rate of clinically
significant prostate cancer in TB+SB scheme. We could find that digital rectal
examination was not identified as an independent predictor in TB alone scheme for
the detection of clinically significant prostate cancer, whereas the family history of
prostate cancer was not included in the logistic regression model in TB+SB scheme.
Apart from the lesions located in peripheral zone, other lesion locations in transitional
zone, anterior fibromusclar zone, and central zone were demonstrated to be paralleled
for the detection rate of clinically significant prostate cancer between these two
schemes. Based on the logistic regression model for TB scheme, lesions with
PI-RADS score of 5 (OR=35.787; 95%CI: 6.576-194.739; p=0.000 ) had higher
possibility of being found to harbour clinically significant prostate cancer than lesions
with PI-RADS score of 4 (OR=6.567; 95%CI: 1.512-28.516; p=0.012). In TB+SB
scheme, there was also a statistically significant increase in the risk of having
clinically significant prostate cancer for lesions of PI-RADS score of 5 (OR= 21.918;
95%CI: 5.271-91.148; p=0.000) compared with lesions of PI-RADS score of 4
(OR=3.049; 95%CI: 1.082-8.589; p=0.035). In brief, when we apply prostate biopsy
to sample patients with positive mpMRI results, family history of prostate cancer
should be given more weight other than digital rectal examination in TB alone scheme.
However, digital rectal examination was more likely to account for the detection of
clinically significant prostate cancer than family history of prostate cancer in TB+SB
scheme.
Table 10. Regression analysis for factors associated with the detection of csPCa in TB scheme
Variables B coefficient OR (95% CI) p value
Age at biopsy (year) 0.107 1.113 (1.058-1.170) 0.000
PSAD 2.999 20.061 (2.0655-194.870) 0.010
Family history of prostate cancer
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No Reference (OR=1.000)
Yes 2.473 11.853 (1.479-95.011) 0.020
Prior negative biopsy
Yes Reference (OR=1.000)
No 1.219 3.382 (1.383-8.272) 0.008
mpMRI PI-RADS score 0.000
PI-RADS 3 Reference (OR=1.000)
PI-RADS 4 1.882 6.567 (1.512-28.516) 0.012
PI-RADS 5 3.578 35.785 (6.576-194.739) 0.000
Location of MRI target 0.006
AS Reference (OR=1.000)
CZ 1.529 4.613 (0.199-106.881) 0.340
PZ 2.530 12.559 (0.924-170.650) 0.057
TZ 0.879 2.409 (0.164-35.412) 0.521
Constant -13.538 0.000 0.000
AFS: anterior fibromusclar zone; CZ: central zone; PZ: peripheral zone; TZ: transitional zone.
Table 11. Regression analysis for factors associated with the detection of csPCa in TB+SB
scheme
Variables B coefficient OR (95% CI) p value
Age at biopsy (year) 0.110 1.116 (1.056-1.180) 0.000
PSAD 3.973 53.130 (4.052-696.718) 0.002
Digital rectal examination
Normal Reference (OR=1.000)
Suspect 0.977 2.692 (1.247-5.661) 0.011
Prior negative biopsy
Yes Reference (OR=1.000)
No 1.749 5.747 (2.408-13.716) 0.000
mpMRI PI-RADS score 0.000
PI-RADS 3 Reference (OR=1.000)
PI-RADS 4 1.115 3.049 (1.082-8.589) 0.035
PI-RADS 5 3.087 21.918 (5.271-91.148) 0.000
Location of MRI target 0.074
AS Reference (OR=1.000)
CZ 1.728 5.628 (0.261-121.262) 0.270
PZ 2.781 16.133 (1.287-202.278) 0.031
TZ 2.155 8.627 (0.646-115.178) 0.103
Constant -13.644 0.000 0.000
AFS: anterior fibromusclar zone; CZ: central zone; PZ: peripheral zone; TZ: transitional zone.
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4 Discussion
4.1 Development of prostate biopsy
It is well known that the prostate is an organ deeply located in the pelvic cavity.
Prostate cancer is one of the malignancies lacking of early symptoms and pain. PSA
screening is commonly used to predict the possibility of having prostate cancer before
identifying the palpable prostate nodule [52-54]. However, histopathology still is the
gold standard of tumor diagnosis. The location and volume of the prostate determines
the difficulties in obtaining samples. The number and position of needle cores in
prostate biopsy has gone through several changes for the sake of better oncological
outcomes and less complications. Research and debates concerning the biopsy
instruments and the strategy of biopsy are still ongoing. Early in 1988, Ragde and
colleagues [55] already addressed that 89 percent of prostate cancers could be
detected using a biopsy gun which has been employed as the standard device
nowadays, while aspiration biopsy only found 51 percent of cancers in all the
specimens of prostate. Prostate biopsy mapping with six cores under the guidance of
transrectal ultrasound advanced by Hodge [56] in 1989 firstly provided the concept of
“systematic sampling”. Systematic sampling was able to reduce observer- and
sampling-related errors. On the basis of sextant biopsy, 8-core, 10-core and 12-core
prostate biopsy were also widely proposed and employed in the past years [57, 58]. It
was reported that 12-core systematic biopsy could maximize the detection rate of
prostate cancer as well as improve the accuracy of determining the Gleason score [59].
12-core systematic biopsy was acknowledged as the standard procedure for all
patients before the emergence of mpMRI, amongst whom it must have harboured
lesions which could be visualized on mpMRI now.
With the advent of mpMRI, combining conventional T2WI imaging with functional
sequences, the likes of DWI and DCE could offset the defect of conventional T2WI
imaging of prostate, increasing the detection of prostate cancer, providing more
additional information of lesions and avoiding unnecessary prostate biopsy [60-62].
Moreover, the mpMRI imaging is reportedly associated with the pathological results
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of postoperative samples acquired from radical prostatectomy, and even could foresee
the recurrence of prostate cancer after focal therapy [63, 64]. MRI/TRUS fusion
targeted biopsy is the product of prostate biopsy based on mpMRI, which is
prevalently used for patients with suspected mpMRI outcomes. This technique allows
urologists to target the suspected lesions directly and makes prostate biopsy turn a
new page. Nevertheless, most scholars are in favor of combining MRI/TRUS fusion
targeted biopsy with systematic biopsy for diagnosis of prostate cancer in patients
with suspected mpMRI results. The aim of my study is to identify the role of
MRI/TRUS fusion targeted biopsy and systematic biopsy in diagnosis of prostate
cancer, respectively and determine the possibility and efficiency using only
MRI/TRUS fusion targeted biopsy for those patients.
4.2 Core length and the detection of prostate cancer
To begin with, our results revealed that the length of apex cores was shorter than its
corresponding value of the length of middle or base cores when implementing
systematic biopsy. It is probably the reason for the low tumor detection rate in apex
region using systematic biopsy. As reported, the raised detection rate of prostate
cancer was related to a longer length of core [51]. Consequently, low cancer detection
rate in apex area is supposed to be the biggest shortcoming of systematic biopsy, in
line with some other studies, where additional needle biopsy on apex could increase
the cancer detection rate [36, 65, 66].
The results of another comparison did show that the average length of total cores with
MRI/TRUS fusion targeted biopsy (TB) followed by 12-core systematic biopsy (SB)
was shorter than the one using only 12-core systematic biopsy in my cohort. In
addition to the effect of sample size, the length of cores in MRI/TRUS fusion targeted
biopsy may be a drag to the overall length of cores in MRI group. This is mainly
because lesions in peripheral zone remain easier and more common to be grasped by
mpMRI and prostate cancer is apt to occur in the peripheral zone [67], which is
hugely close to the rectum. Thus, the length of cores tends to be shorter in MRI/TRUS
fusion targeted biopsy. But it is not surprising that the overall cancer detection rate for
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patients in MRI group was higher than that in standard group, because targeted biopsy
could detect more clinically significant prostate cancers than systematic biopsy due to
its high efficiency [68-72]. My study comparing MRI group with standard group
concerning the detection rate of clinically significant prostate cancer has also yield the
same trends with the detection rate of overall prostate cancer. Hence, MRI-based
biopsy is an effective approach to detect csPCa. However, MRI/TRUS fusion targeted
biopsy was performed with a concurrent systematic biopsy for patients in MRI group.
4.3 The role of targeted biopsy and systematic biopsy
After identifying the relative contribution of MRI/TRUS fusion targeted biopsy and
systematic biopsy in our cohorts (MRI group) and comparing TB plus SB approach
with SB approach, we found it to be challenging to select the most suitable approach.
Though no significantly statistical difference was demonstrated between TB plus SB
approach and TB alone approach regarding the detection rate of clinically significant
prostate cancer for patients with positive mpMRI results, the detection rate of csPCa
for all lesions in TB combined with SB approach seems to have potential superiority
over TB alone approach. We speculate that it actually showed the same trends and
results because TB plus SB approach still showed that it had higher efficiency to
detect csPCa than TB alone approach among 139 patients in MRI group. The
difference is just that there was no statistical significance. However, the detection rate
of clinically insignificant prostate cancer in TB plus SB approach was also
remarkably higher than that in TB alone approach, both in the analysis for patients
and lesions. This implies that elevated detection rate of clinically significant prostate
cancer is almost in equal proportion with the increased detection rate of clinically
insignificant prostate cancer when comparing TB plus SB approach with TB alone
approach, no matter in the analysis for patients (6.5% versus 7.9%) or lesions (12.7%
versus 11.3%). Thus, it does not seem to be worth performing combined approach, in
the case of TB alone approach having possessed such high efficiency in detecting
clinically significant prostate cancer, which at least accounted for approximately 80
percent of total prostate cancer in patients with positive mpMRI results in our study.
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But the corresponding fractions of clinically significant prostate cancers would be
missed as well if only performing TB alone approach. Moreover, there are some
studies, reporting that TB alone approach is not predominant in the detection of
clinically significant prostate cancer over SB approach [73], even for the detection of
overall prostate cancer [74]. They suggest that additional systematic biopsy would
also be needed in MRI-based biopsy strategy, and targeted biopsy cannot completely
replace the role of systematic biopsy [75-77].
4.4 MRI parameters and the detection of prostate cancer
In order to shed light on this dilemma, a correlation analysis between mpMRI
parameters and the detection rate of clinically significant prostate cancer for TB+SB
approach and TB alone approach were performed in this study, respectively. The
diameters of lesions on mpMRI for predicting the detection of csPCa was comparable
between these two approaches, though lesion diameter was reportedly linked to the
risk of prostate cancer and diameter ≥ 15cm was reported to be the best threshold to
distinguish the PI-RADS 4 and 5 lesions [78, 79]. The number of ROIs as a predictive
factor of clinically significant prostate cancer detected by TB+SB approach was also
not different from it identified by TB alone approach, in keeping with previous studies
that the number of ROI as variable was not included in the nomogram of MRI-based
targeted biopsy strategy for the detection of clinically significant prostate cancer [80,
81].
Moreover, TB alone approach has been demonstrated to have awesome results for
yielding clinically significant prostate cancer in PI-RADS 3 lesions or PI-RADS 5
lesions without increasing additional detection of clinically insignificant prostate
cancer. Nevertheless, TB+SB approach could provide higher detection rate of
clinically significant prostate cancer for PI-RADS 4 lesions. It might be that clinically
significant prostate cancer is highly likely to present in PI-RADS 5 lesions, and
additional systematic biopsy could not be more supportive, but only raise the
detection rate of clinically insignificant prostate cancer. PI-RADS 3 lesions on
mpMRI itself featuring equivocality, but with least chance being malignant in all
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lesions on mpMRI, the detection rate for prostate cancer detected by targeted biopsy
approach or systematic approach was quite low, let alone for clinically significant
prostate cancer. But PI-RADS 4 lesions as an intermediate level need contribution of
detection from both targeted biopsy and systematic biopsy. Additionally, as Hakozaki
showed, targeted biopsy could upgrade Gleason score of PI-RADS 4 lesions
compared with systematic biopsy, combination of TB and SB could perform the
highest detection rate of clinically significant prostate cancer [82].
Lastly, TB alone approach was observed to yield paralleled detection rate of clinically
significant prostate cancer for lesions in peripheral area over TB+SB approach. My
data are consistent with the previous study, documenting that targeted biopsy alone
approach is able to detect 100% of clinically significant prostate cancer for PI-RADS
5 lesions in peripheral zone and 88% of that in patients with PIRADS 4 lesions in
peripheral zone, respectively [83]. To sum up, targeted biopsy alone could be
considered in specific cases.
4.5 Risk factors for the detection of clinically significant prostate cancer
Multivariate logistic regression analysis indicated that age at biopsy, PSAD, prior
negative biopsy, PI-RADS score, and the location of lesion were common risk factors
in TB+SB approach and TB alone approach for the detection of clinically significant
prostate cancer. PSAD and PI-RADS score were the two most important predictors
for clinically significant prostate cancer in TB+SB approach as well as TB alone
approach. Besides, PSAD and PI-RADS score were found to be not only the
predictive factors for naive patients [84, 85], but also two highly strong risk factors
for patients undergone repeated prostate biopsy [86]. The difference was that family
history of prostate cancer was the independent risk factor for TB alone approach,
whereas suspect findings in digital rectal examination increased the likelihood of
detecting clinically significant prostate cancer in TB+SB approach, not family history
of prostate cancer. Bjurlin, et al [87] also reported that abnormal digital rectal
examination could independently predict the risk of clinically significant prostate
cancer using TB+SB approach for repeated biopsy cases. On the other hand, digital
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rectal examination was the decisive factor associated with clinically significant
prostate cancer in systematic biopsy [88, 89]. Hence, we infer that the digital rectal
examination would be contained in multivariate logistic regression model when
performing the combined approach. Moreover, family history of prostate cancer is a
risk factor for the detection of clinically significant prostate cancer in systematic
biopsy [90]. However, clinically significant prostate cancer in TB alone approach will
rather be associated with mpMRI parameters, such as PI-RADS score, not be
highlighted with the risk factors which play a crucial role on systematic biopsy.
As discussed in 4.2, 4.3 and 4.4 parts, my findings coincide with others that TB+SB
approach have higher detection rate of clinically significant prostate cancer compared
with TB alone approach, but identifying more clinically insignificant prostate cancer
in the meantime [91, 92]. Targeted biopsy alone approach will miss a few clinically
significant prostate cancers, which is also similar with the point of view of
Delongchamps [93], who showed that 4% of clinically significant prostate cancers
would be missed in patients with positive mpMRI results if only using targeted biopsy.
Hence, we believe that well-selected patients could be the candidates for undergoing
targeted biopsy alone approach. It should be noted that MRI-based biopsy strategy has
been confirmed as a cost-effective protocol, offering good oncological outcomes [94],
but it would also rely on the experience of clinician, no matter the use of rigid or
elastic registration for MRI-based targeted biopsy [95].
4.6 Limitations of the study
Obviously, retrospective study design is the main flaw in my study. All the patients
who underwent the prostate biopsy were treated in a single institution, Diakonie
Klinikum Stuttgart, which may lead to sample selection bias. In addition, we just
attempted to calculate the relative detection contribution by MRI/TRUS fusion
targeted biopsy alone approach and 12-core systematic biopsy alone approach in the
same session, then simulatedly to compare the oncological efficacy between
MRI/TRUS fusion targeted biopsy and MRI/TRUS fusion targeted biopsy followed
by a 12-core systematic biopsy. Here I did not conduct real comparisons in practice
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between the MRI/TRUS fusion targeted biopsy alone approach and the combined
approach for patients with positive mpMRI outcomes. Furthermore, the small series
of patients in my study were not sufficient for a convincing and influential research,
which could weaken the statistical efficiency. Larger sample size should be used in
further analysis. Moreover, the whole samples were not biopsied by the same clinician
and digital rectal examination were mostly performed by different urologists, which
could be affected by subjective feelings. Additionally, another bias is that eight
patients were measured by 1.5T MRI scan in spite of most patients tested by 3.0T
MRI scan, which may result in the possibility of missing some small underlying
tumors. Undetected tumors could contribute to the alternations of MRI parameters of
lesions in the cohorts, for instance, the numer of region of interest, the composition of
the PI-RADS and the diameter of lesions. Lastly, those who underwent transperineal
MRI-targeted biopsy from January 2017 to March 2018 in our centre were not
included in my analysis and only those who underwent tranrectal biopsy approach
were recruited in the study. As for some patients strongly doubted with apex tumor, it
is transperineal MRI-targeted biopsy that may be superior, not transrectal biopsy
strategy.
4.7 General conclusions and outlook
In general, MRI/TRUS fusion targeted biopsy together with systematic biopsy could
detect more clinically significant prostate cancers than MRI/TRUS fusion targeted
biopsy alone approach, but it could also cause equal chance of more clinically
insignificant prostate cancers to be detected. However, MRI/TRUS fusion targeted
biopsy alone approach has been proved to be a sophisticated method, especially for
lesions located in peripheral zone and lesions with PI-RADS score of 3 and 5. For
those with specific lesions above who have an urge to undergo biopsy with fewer
needle cores taken from prostate, MRI/TRUS fusion targeted biopsy without
systematic biopsy might be an effective method to achieve comparable oncological
outcomes over combined approach, but the risk of missing clinically significant
prostate cancer also needs to be communicated to those patients before the biopsy.
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Naturally, patients with positive mpMRI results who have a great psychological
burden of missing clinically significant prostate cancer are still the preferred
candidates for MRI/TRUS fusion targeted biopsy followed systematic biopsy. Besides,
software registration for MRI/TRUS fusion targeted biopsy requires additional fusion
equipment as well as trained clinicians. It is still a challenge to select MRI/TRUS
fusion targeted biopsy for those in less developed areas of medical care, in which
systematic biopsy would still be the only option. There is no absolutely perfect biopsy
strategy for patients with positive mpMRI results so far. Every patient should be
individually assessed and discussed in the clinical decision making. Prospective,
multicentric and randomised trials are valued and required to confirm my conclusions
in the future. We also look forward to discovering some new molecular biomarkers
such as PCA3 [96, 97], which has been approved by FDA in order to carry out a risk
assessment at the molecular level before the prostate biopsy. Even integrating the data
of transcriptomics [98], metabonomics [99] and proteomics [100, 101] of prostate
cancer, points out the possibility of detecting clinically significant prostate cancer as
well as clinically insignificant prostate cancer for each patient, comprehensively
determining the biopsy strategy for patients with positive mpMRI results and avoiding
overdiagnosis and overtreatment of prostate cancer.
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5 Summary
To date randomised systematic biopsy guided by transrectal ultrasound is still the
standard care for diagnosis of prostate cancer, as prostate cancer is characterised by
multifocal growth, high heterogeneity and lack of typical symptoms. Nevertheless, in
the wake of the development of new molecular imaging on diagnosis of disease,
multiparametric magnetic resonance imaging (mpMRI) has been progressively used
in urology in recent years. There is growing evidence that magnetic resonance
imaging/transrectal ultrasound (MRI/TRUS) fusion targeted biopsy with merits of
detecting more clinically significant prostate cancers (csPCa) and fewer needle cores
taken from the prostate is becoming a promising method in prostate biopsy, especially
for patients with positive mpMRI results. More thrillingly, at the beginning of this
year a multicentric trial, PRECISON, has suggested that MRI/TRUS fusion targeted
biopsy could be performed solely in these patients and it could achieve utterly
satisfactory outcomes. However, it is highly debated that whether it is still necessary
to add a 12-core systematic biopsy after MRI/TRUS fusion targeted biopsy to these
patients, which is backed by the point of view that MRI/TRUS fusion targeted biopsy
is also likely to miss some cases with csPCa. Currently, majority of centres still
conservatively adopt MRI/TRUS fusion targeted biopsy followed by a 12-core
systematic biopsy in patients who have suspicious lesions on mpMRI. This work aims
to evaluate the possibility and accuracy of only carrying out MRI/TRUS fusion
targeted biopsy without 12-core systematic biopsy in patients with positive mpMRI
results. The exploratory findings demonstrated that MRI/TRUS fusion targeted biopsy
combined with systematic biopsy could obviously detect more prostate cancers, to a
certain extent, more clinically significant prostate cancers compared with MRI/TRUS
fusion targeted biopsy alone approach, but it also led to more risk of clinically
insignificant prostate cancer to be detected. Further analysis illustrated that
MRI/TRUS fusion targeted biopsy alone approach was superior to the combined
approach without detecting additional clinically insignificant prostate cancers in
lesions with PI-RADS score of 3 and 5 as well as for lesions situated in peripheral
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zone when we considered the correlation between mpMRI parameters of lesions and
the detection rate of csPCa. Moreover, the number of region of interest (ROI) as well
as the diameter of lesions were found perhaps not the deciding factors between
MRI/TRUS fusion targeted biopsy alone approach and the combined approach.
Multivariate logistic regression analysis showed that in addition to several common
risk factors such as age at biopsy, PSAD, prior negative biopsy, PI-RADS score, and
the location of lesion, family history of prostate cancer was an independent predictor
for csPCa in MRI/TRUS fusion targeted biopsy alone approach, while digital rectal
examination required to be more highlighted using combined approach. Hence,
MRI/TRUS fusion targeted biopsy approach could achieve as great the oncological
efficacy as combined approach and may be warranted in selective cases with positive
mpMRI results. Further well-designed, prospective, multicentric and randomised
trials are awaited to validate this conclusion and better define the role of MRI/TRUS
fusion targeted biopsy.
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6 Zusammenfassung
Bis heute ist die randomisierte systematische ultraschallgesteuerte transrektale
Prostatastanzbiopsie Standard zur Diagnose des Prostatakarzinoms, da dieses sich
durch multifokales Wachstum, hohe Heterogenität und das Fehlen typischer
Symptome kennzeichnet. Im Zuge der Entwicklung neuer molekularer
Bildgebungsverfahren zur Diagnose der Erkrankung, hat die multi-parametrische
Magnetresonanztomographie (mpMRI) in den letzten Jahren zunehmend Einzug in
der Urologie gehalten. Es gibt immer mehr Belege dafür, dass die
MRT-Ultraschall-Fusionsbiopsie mit einem besseren Nachweis von klinisch
signifikantem Prostatakrebs (csPCa) bei geringerer Anzahl entnommener Stanzen aus
der Prostata zu einer vielversprechenden Biopsie-Methode, besonders bei Patienten
mit positiven MRT-Befunden, wird. Spannend ist, dass zu Beginn dieses Jahres in
einer multizentrische Studie, PRECISON, vorgeschlagen wurde, dass eine
MRT/TRUS Fusionsbiopsie speziell bei diesen Patienten durchgeführt werden kann
und zu völlig zufriedenstellenden Ergebnissen führt. Die Notwenigkeit einer
zusätzlich systematischen 12-Kern-Stanzbiopsie im Anschluss an eine
MRT-Ultraschall-Fusionsbiopsie, steht weiterhin zu Debatte. Dies wird durch den
Standpunkt einiger Studien unterlegt, dass eine alleinge zielgerichtete Biopsie mittels
MRI / TRUS-Fusion einige Fälle mit csPCa uebersieht. Gegenwärtig findet die
alleinige Fusionsbiopsie in der Mehrzahl der Zentren bei Patienten mit verdächtigen
Läsionen im mpMRI eher zurückhaltend Anwendung. Diese Arbeit zielt darauf ab, die
Möglichkeit und Genauigkeit der alleinigen Durchführung einer
MRT-Ultraschall-Fusionsbiopsie ohne systematische 12-Kern-Stanzbiopsie bei
Patienten mit positiven MRT-Ergebnisse zu bewerten. Die explorativen Ergebnisse
zeigten, dass eine MRT-Ultraschall-Fusionsbiopsie in Kombination mit einer
systematischen Biopsie offensichtlich mehr Prostatakarzinome, bis zu einem gewissen
Grad ebenfalls mehr klinisch signifikante Prostatakarzinome im Vergleich zur
alleinigen Fusionsbiopsie detektieren konnte. Jedoch führte dies auch zur Detektion
klinisch unbedeutender Prostatakarzinome. Der weitere Vergleich zeigte, dass ein
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alleiniger MRT/TRUS-Fusionsbiopsie-Ansatz der Kombination beider Stanzverfahren
überlegen war, ohne zusätzliche klinisch unbedeutende Karzinome bei Läsionen mit
PI-RADS-Score von 3 und 5 oder solchen mit Lokalisation in der peripheren Zone zu
detektieren, wenn wir die Relevanz der Korrelation zwischen den MRT-Parametern
der Läsionen und der Detektivrate von csPCa separat betrachten. Ferner wird
angenommen, dass die Anzahl der „regions of interest“ (ROI) sowie der Durchmesser
der Läsionen möglicherweise nicht für den Nachweis von csPCa in sowohl dem MRI
/ TRUS-Fusionsbiopsie-Ansatz als auch dem kombinierten Ansatz ausschlaggebend
sind. Multivariate logistische Regressionsanalysen zeigten, dass die
Familienanamnese zusätzlich zu mehreren allgemeinen Risikofaktoren wie Alter bei
Biopsie, PSAD, vorheriger negativer Biopsie, PI-RADS-Score und Läsionsort, einen
unabhängigen Prädiktor hinsichtlich eines csPCa bei alleiniger
MRT-Ultraschall-Fusionsbiopsie darstellte, während die digitale rektale Untersuchung
in Verbindung mit einem kombinierten Ansatz stärker hervorgehoben werden sollte.
Daher könnte ein alleiniger MRT/TRUS-Fusionsbiopsie-Ansatz eine ebenso große
onkologische Effizienz vorweisen wie die Kombination aus Fusionsbiopsie und
systematischem Biopsieschema und kann in ausgewählten Fällen mit positiven
mpMRT-Ergebnissen gerechtfertigt sein. Weitere gut geplante, multizentrische,
prospektive und randomisierte Studien sind weiterhin nötig, um unsere
Schlussfolgerungen zu validieren und die Rolle der MRT-Ultraschall-Fusionsbiopsie
in der Zukunft besser zu definieren.
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Abstract: 
Objective: To compare the oncological and functional outcomes in localised 
prostate cancer patients who received non-whole-gland High-intensity 
focused ultrasound (HIFU) with patients who received whole-gland HIFU 
therapy.  
Patients and Methods: 86 patients from September 2012 to January 2017 
in our center were retrospectively analysed. Oncological outcomes included 
histological absence of prostate cancer, biochemical disease-free survival 
(BDFS) as well as the absence of lesions suspected for harboring prostate 
cancer in mpMRI. Regarding functional outcomes, we determined 
International prostate symptom score (IPSS), pad-free rate, pad-free and 
leakage-free rates as well as International index of erectile function-5 
(IIEF-5).  
Results: Out of the 86 patients, 25 patients who underwent non-whole-
gland HIFU and 61 patients who underwent whole-gland HIFU were 
enrolled in our one-year follow-up study. There were no significant 
differences in histological absence of prostate cancer (p=0.655), BDFS 
(p=0.820), PSA nadir (p=0.453) and absence of suspicious lesions in 
mpMRI (p=0.633) between non-whole-gland HIFU group and whole-gland 
HIFU group. However, compared with the whole-gland HIFU, the non-
whole-gland HIFU group had fewer IPSS at 1 month (8.64±3.63 versus 
10.85±6.10), a longer time to PSA nadir (5.04±2.07 versus 3.83±1.65), 
less temporary urine retention rate (20.0% versus 44.3%), less 
complication rate especially urinary tract strictures (4% versus 26.2%), 
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whereas pad-free rate, pad-free and leakage-free rates and IIEF scores 
were comparable.  
Conclusion：Non-whole-gland HIFU is a promising type of treatment for 
localized prostate cancer with satisfactory oncological results with less 
impairment of functional outcomes and complications compared to whole-
gland HIFU, but it requires longer follow-up and larger samples of 
randomized control trials.   
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  Abbreviation                         Full name 
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BDFS                    Biochemical Disease-free Survival 
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ABSTRACT 
Objective: To compare the oncological and functional outcomes in localised prostate 
cancer patients who received non-whole-gland High-intensity focused ultrasound 
(HIFU) with patients who received whole-gland HIFU therapy. 
Patients and Methods: 86 patients from September 2012 to January 2017 in our 
center were retrospectively analysed. Oncological outcomes included histological 
absence of prostate cancer, biochemical disease-free survival (BDFS) as well as the 
absence of lesions suspected for harboring prostate cancer in mpMRI. Regarding 
functional outcomes, we determined International prostate symptom score (IPSS), 
pad-free rate, pad-free and leakage-free rates as well as International index of erectile 
function-5 (IIEF-5). 
Results: Out of the 86 patients, 25 patients who underwent non-whole-gland HIFU 
and 61 patients who underwent whole-gland HIFU were enrolled in our one-year 
follow-up study. There were no significant differences in histological absence of 
prostate cancer (p=0.655), BDFS (p=0.820), PSA nadir (p=0.453) and absence of 
suspicious lesions in mpMRI (p=0.633) between non-whole-gland HIFU group and 
whole-gland HIFU group. However, compared with the whole-gland HIFU, the 
non-whole-gland HIFU group had fewer IPSS at 1 month (8.64±3.63 versus 
10.85±6.10), a longer time to PSA nadir (5.04±2.07 versus 3.83±1.65), less temporary 
urine retention rate (20.0% versus 44.3%), less complication rate especially urinary 
tract strictures (4% versus 26.2%), whereas pad-free rate, pad-free and leakage-free 
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rates and IIEF scores were comparable. 
Conclusion：Non-whole-gland HIFU is a promising type of treatment for localized 
prostate cancer with satisfactory oncological results with less impairment of 
functional outcomes and complications compared to whole-gland HIFU, but it 
requires longer follow-up and larger samples of randomized control trials.    
INTRODUCTION 
There is a great debate about the treatment options for prostate cancer, with 
disagreement on whether patients with localized tumor ought to undergo deferred 
treatment or radical interventions, and on the most suitable type of management.  
Immediate radical interventions burden patients with more risks of treatment-related 
side-effects, especially urinary incontinence, and to some extent are more likely to 
constitute overtreatment compared to active surveillance [1]. Nevertheless, those who 
choose active surveillance face uncertainty of tumor control and anxieties about 
subsequent series of psychological problems like emotional distress [2]. On the other 
hand, the latest European Association of Urology (EAU) guidelines have further 
specified that active surveillance can be considered not only for patients with low-risk 
tumor, but can also be expanded to selected patients with favorable intermediate-risk 
localized prostate cancer (Gleason score 3+4), despite carrying increased risk of 
metastases [3]. Hence, we are more puzzled how to balance morbidity of treatment 
and quality of life and, at the same time, avoid overtreatment for low- and 
intermediate-risk localized cases. There is need to explore new concepts of treatment 
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to help both urologists and oncologists make better clinical decisions.   
Transrectal high-intensity focused ultrasound (HIFU) therapy, as an alternative 
therapy, is increasingly used as primary treatment of localised prostate cancer for 
which radical prostatectomy and definitive radiotherapy, have been considered as 
constituting gold standard management for a long time. Moreover, HIFU is also now 
used as salvage therapy for recurrent disease [4]. There is already evidence that the 
chances for overall-survival (OS) and metastasis-free survival (MFS) up to five years 
are the same for both patients who have undergone whole-gland HIFU treatment and 
radical prostatectomy [5]. However, with the emergence of radiographic technologies 
such as multiparametric magnetic resonance imaging (mpMRI) helping to distinguish 
clinically significant from clinically insignificant prostate cancer, and the concept of 
precision medicine on the other hand, there are already some cohort studies that have 
focused on the use of hemiablation as the non-whole-gland HIFU for prostate cancer 
treatment[6, 7, 8]. Ahmed et. al., [9,10] have advanced the theory of index lesion and 
carried out a study of focal ablation targeting the index lesion in multifocal localised 
prostate cancer, which may corroborate the thesis that metastatic phenotype have only 
monoclonal origins and that secondary lesions are not attributed to PSA biochemical 
failure [11,12]. However, it is unclear and scarcely reported whether the oncological 
and functional outcomes of non-whole-gland HIFU and whole-gland HIFU are 
distinct. 
The aim of our study is to primarily compare the one-year oncological and functional 
outcomes between non-whole-gland HIFU and whole-gland HIFU for the primary 
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treatment of localized prostate cancer, in order to establish how HIFU may be 
integrated into our clinical practice best.    
PATIENTS AND METHODS 
Patient Preparation      
86 localized prostate cancer patients without metastases verified via bone scan, pelvic 
CT or MRI scan from September 2012 to January 2017 were enlisted in our 
retrospective study. Of these patients, twenty-five underwent the primary 
non-whole-gland HIFU therapy, including 13 hemiablations and 12 zonal ablations. 
All other patients were treated with a whole-gland HIFU. Patients were informed of 
all possible treatment options and were counseled about possible risks. Prostate cancer 
was detected by systematically transrectal ultrasound-guided, random biopsy of 12 
cores in all patients. When the MRI scan showed suspicious areas within the prostate, 
additional targeted fusion-biopsies were performed either through a transperineal or 
transrectal approach to increase detection rate. Seven patients in our study received 
androgen deprivation therapy, which had no statistical significance in 
non-whole-gland and whole-gland group.  
Transrectal High-Intensity Focused Ultrasound Procedure 
Under general anesthesia, all patients received a single-shot antibiotic prophylaxis. 
After sterile placement of transurethral Foley catheter patients are positioned in a 
lateral posture. Before insertion of the transducer, the prostate and rectum is examined 
and the anal sphincter is gradually and carefully stretched. Non-resistant movement is 
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indispensable for procedure. In our scheme, to ensure accuracy and reduce bias, the 
prostate is divided into 24 zones, as shown in Figure 1. In the past we mostly used the 
whole-gland HIFU therapy in our clinic. We also applied three types of 
non-whole-gland HIFU ablations – Hemiablation, zonal ablation and target ablation – 
based on patient-specific treatment plans (Figure 2). It must be pointed out that in this 
series only salvage cases were treated by targeted ablation. This was planned on the 
basis of preoperative mpMRI and real-time transrectal ultrasonography images during 
HIFU and confirmed by fusion biopsies. Taking the safty distance between the rectum, 
nerve bundle, sphincter and apex of prostate into account, therapeutic range is 
contoured precisely through real-time three-dimensional ultrasonic planning at the 
console. As a landmark alleviating treatment planning we used an indwelling catheter. 
In a whole-gland Hifu ablation it was left in-situ during the treatment of the left lobe 
and removed during the treatment of the right lobe and the urethral area of the 
prostate.  
Follow-up procedure 
As a follow-up procedure, patients who underwent the HIFU therapy were subjected 
to serum prostate specific antigen (PSA) level tests quarterly during the first year. 
Biochemical disease-free survival (BDFS) at 12 months was defined using the 
Phoenix criteria (PSA nadir + 2 ng/ml). Scheduled mpMRI comprising T2-weighted, 
diffusion-weighted and dynamic contrast-enhanced sequences was used to identify the 
tumor location and possible local invasion after HIFU procedure at 6 months and 12 
months, and a final score determined using the Prostate Imaging Reporting and Data 
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System (PI-RADS) developed by the European Society of Urological Radiology 
(ESUR). Our primary oncological outcome was histological absence of prostate 
cancer at 12 months. However, in our research, systematic postoperative prostate 
biopsy at 12 months was not a routine procedure because most patients refused 
repeated biopsies except PSA or mpMRI showed clinical evidence of further 
recurrence. Thus, we only performed control prostate biopsies, when there was 
biochemical or imaging signs of recurrence. Functional assessments were mainly 
carried out according to the following parameters: an international prostate symptom 
score (IPSS) questionnaire was used to estimate the lower urinary tract symptom 
(LUTs) preoperatively and postoperatively; Continence status was defined as 
‘pad-free’ or ‘pad-free and leakage free’; the International index of Erectile function-5 
(IIEF-5) score was used to assess sexual function including erectile confidence, ability 
for penetration, maintaining and completing intercourse as well as achieving sexual 
satisfaction. 
Statistical analyses 
Statistical description and analysis of quantitative data were performed using the 
mean ± standard deviation and t-test, respectively. Statistical analysis of enumeration 
data analysis was applied by χ
2
-test. All statistical analyses were carried out using the 
Statistical Package for Social Science (SPSS version 21.0) software. p<0.05 was set to 
be statistically significant.   
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RESULTS 
Baseline demographics 
Of the 86 patients included in this analysis, a group of 25 patients were subjected to 
non-whole-gland HIFU treatment, out of which 13 underwent hemiablation and 12 
were treated by zonal ablation. All basic characteristics of the 86 patients are listed in 
Table 1. Although we have indicated the results from both hemiablation and zonal 
ablation in the non-whole-gland HIFU group, all statistical results were derived from 
the comparison carried out between the entire non-whole-gland HIFU and the 
whole-gland HIFU group. There were no significant differences concerning the 
parameters of age (p=0.058), PSA (p=0.290), Gleason score (p=0.308), risk 
classification (p=0.099) and clinical T stage (p=0.255) before treatment between the 
two groups. Nonetheless, the prostate volumes before treatment in non-whole-gland 
group were greater than in the whole-gland group (p=0.000). This is in accordance 
with the preoperative prostate volume reduction rate (p=0.000), as 36 percent of the 
patients underwent the transurethral resection of prostate (TURP) or thulium laser 
enucleation of prostate in the non-whole-gland HIFU group, which was less than 83.6 
percent of whole-gland HIFU group. 
Oncological outcomes 
Among the 25 patients subjected to the non-whole-gland HIFU, preoperative and 
postoperative PSA at 3 months, 6 months, and 12 months were 8.39±6.84, 2.08±1.70, 
1.44±1.06, 2.13±1.37 (ng/ml) In the whole-gland HIFU group PSA were 6.70±5.97, 
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1.18±1.50, 1.46±1.89, and 1.79±1.85, respectively (Figure 3A and B). PSA kinetics 
indicated that the PSA decreasing rates by 3 months and 6 months from baseline were 
comparable between these two groups, whilst a significant difference of PSA levels 
could be found at 3 months (p=0.026). No difference was observed in terms of PSA 
nadir (p=0.453), whereas PSA-Nadir was reached markedly earlier in the whole-gland 
HIFU group compared to patients in the non-whole-gland HIFU group (3.83±1.65 
versus 5.04±2.07 months; p=0.006). Histological absence of prostate cancer at 12 
months was 20 of 25 patients (80.0%) in non-whole-gland HIFU group, which was 
comparable to 52 of 61 patients (85.2%) in whole-gland HIFU group (p=0.655). 
There was no remarkable difference observed in non-whole-gland and whole-gland 
HIFU group according to the BDFS (96.0% versus 91.8%; p=0.820). No mpMRI 
measurable prostate cancer occurred in 20 (80%) patients of non-whole-gland HIFU 
group, which was also comparable to 53 (86.8%) patients of whole-gland HIFU group 
(p=0.633). Nine patients from the whole-gland HIFU group and five patients from the 
non-whole-gland HIFU group who had a PSA relapse at 12 months after primary 
HIFU treatment were treated by a salvage HIFU with an according energy adjustment. 
All the results regarding oncological efficacy are summarized in Table 3.  
Functional outcomes 
As presented in Table 4, IPSS at 0 month, 1 month, 3 months, and 12 months in the 
non-whole-gland HIFU group were 4.88±2.83, 8.64±3.63, 5.44±3.06, and 4.56±2.16, 
respectively and 5.20±4.33, 10.85±6.10, 6.21±5.07, and 5.36±4.36 in the whole-gland 
HIFU group, respectively. IPSS of patients who received non-whole-gland HIFU 
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therapy at 1 month were less than those of patients treated to whole-gland HIFU 
(p=0.042). Notably, IPSS scores at 1 month were significantly higher than IPSS 
baseline scores for patients of both the non-whole-gland HIFU group and the 
whole-gland HIFU group. There were no differences noted at 3 months and 12 
months within each group (Figure 3C and D). Postoperative temporary urine retention 
was found more frequently in the whole-gland HIFU group than in the 
non-whole-gland HIFU group (44.3% versus 20%; p=0.035). However, the incidence 
of urinary tract infection in the non-whole-gland HIFU group was the same as in the 
whole-gland HIFU group (p=0.297). When comparing erectile dysfunction of both 
groups, no significant difference in IIEF scores could be detected (IIEF score of the 
non-whole-gland group: 19.36±3.56 at 0 month, 13.00±4.90 at 3 months, 15.64±4.91 
at 12 months versus 18.48±3.65 at 0 month, 12.07±4.48 at 3 months, 15.15±4.57 at 12 
months in the whole-gland group; Figure 3E and F). Likewise, continence was also 
evaluated at 0 month, 3 months, and 12 months. Our findings showed that the 
proportion of the pad-free rates, as well as the pad-free and leakage free rates of the 
whole-gland HIFU group was not different from the patients in the non-whole-gland 
HIFU. With regards to postoperative complications, 16 patients in the whole-gland 
HIFU group displayed urinary strictures compared to only one patient in the 
non-whole-gland HIFU group (p=0.040). Moreover, two patients from the 
whole-gland HIFU group suffered a vesico-rectal fistula and one suffered an 
intra-abdominal abscess. Both, vesico-rectal fistula and intra-abdominal abscess were 
not identified in the non-whole-gland HIFU group. 
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DISCUSSION 
Focal therapy in patients with low- and intermediate-risk localized prostate cancer is 
regarded as posing a challenge to the conventional notion that prostate cancer is a 
heterogeneity-abounded malignancy in every sense, including the clinical, spatial, 
morphological and genetic diversity [13, 14]. Good local tumor control is essential for 
the prognosis of prostate cancer patients[15, 16]. How to achieve a good local control 
is an intractable problem, usually experienced in focal therapy. In our study, we have 
compared the local tumor control and functional results between non-whole-gland 
HIFU and whole-gland HIFU treatment, to establish the advantages and 
disadvantages of non-whole-gland treatment as a focal therapy. 
Based on data analysis conducted in this study, the PSA at 3 months and time to PSA 
nadir for whole-gland HIFU are higher than those for non-whole-gland HIFU. 
However, there are no differences of PSA at 6 months and at 12 months, as well as the 
PSA nadir. These results confirm the widely held belief that benign prostate tissue can 
also contribute to PSA level, thus hindering PSA level to PSA nadir [17]. Even a tiny  
tumor lesion which cannot be detected by the current image techniques contributes to 
a slight difference. The recovery of PSA to the same level at 12 months and BDFS at 
12 months indicate that in spite of undergoing a non-whole-gland HIFU procedure, 
the tumor is not in progression, at least at the biochemical level. It can also be 
confirmed by imaging and repeated biopsies that the absence of prostate cancer in the 
non-whole-gland HIFU group at 12 months were comparable to that in the 
whole-gland HIFU group. Moreover, all the relapsed patients after the primary HIFU 
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treatment could be successfully treated using salvage HIFU. Non-whole-gland HIFU 
would not have increased the difficulties and decrease possibilities of salvage 
treatment, which were also identified by other reports [18,19].  
No significant changes were observed in IPSS scores for urinary function at 12 
months compared with the baselines in both groups. However, a sharp increase in 
IPSS at 1 month was found within both groups, similar to other studies [20, 21]. It is 
noteworthy that IPSS at 1 month was also higher in the whole-gland HIFU group than 
in the non-whole-gland HIFU group. Similarly, the incidence of urinary retention was 
higher in the whole-gland HIFU group. We speculate that it might be caused by longer 
operation time, greater energy transfer to the gland causing more edema and swelling. 
Erectile functions recovered to pre-operative levels, though in the non-whole-gland 
HIFU group no negative impact on erectile functions could be observed. Yap and 
colleagues [22] have pointed out that the only determinants of erectile function after 
HIFU therapy is the preoperative erectile function status. Furthermore, even though 
the incontinence rates are the same for both groups, severe complications such as 
urinary tract stricture and fistula formation were not observed in the non-whole-gland 
HIFU group. This observation suggests the non-whole gland concept might show a 
more favourable profile of adverse events. 
Non-whole-gland HIFU may be regarded as a in-between concept in the range of 
active surveillance and radical treatment, e.g. radical prostatectomy or external beam 
radiation therapy. It offers acceptable oncological control, causing less frequent 
adverse effects compared to the whole-gland HIFU regime. However, no significant 
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differences have been discovered in the functional outcomes of the two types of 
management at 12 months. Meanwhile HIFU therapy as such, may markedly reduce 
patients’ psychological burden with low- and intermediate-risk prostate cancer. 
Therefore HIFU therapy may be the optimal concept for those patients, who are unfit 
for major surgical interventions or are reluctant to undergo active surveillance. 
Considering worries about side effects, especially the use of a non-whole-gland 
treatment strategy might meet concerns best.  
Retrospective design constitutes the predominant limitation in our study. Whole-gland 
HIFU was basically used in our center before 2014 wherever the lesion was located 
and no matter how many lesions were present. In addition, HIFU device may also be 
considered as a heterogeneity factor in our study, as FocalOne HIFU was introduced 
to our center in 2016. FocalOne HIFU might be different from the device used before 
2016 at our clinic. Furthermore, only eight patients without the PSA biochemical 
recurrence and postoperative measurable mpMRI signs consented to have a re-biopsy 
during the follow-up process and we consider the patients who didn’t undergo the 
re-biopsy without PSA recovery and suspicious lesions in MRI after HIFU treatment 
as histological absence of prostate cancer. This is a factor that could influence the 
oncological outcome in both groups. Hence, there is need for further p ospective, 
randomised, multicenter and comparative studies featuring active surveillance, 
non-whole-gland HIFU and whole-gland HIFU, and even the radical prostatectomy 
and radiation, in order to reach more consensuses on patients selection criteria, as well 
as a standardised follow-up scheme after focal ablation therapy.  
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FIGURE LENGENDS 
Figure 1. Diagrammatic depiction of zones of prostate in HIFU treatment from 
the transverse base, middle, and apex plane, respectively.  
Figure 2. Diagram of four different HIFU treatments for prostate cancer in our 
centre.  
(A) Diagram of whole-gland HIFU treatment. Blue solid edge: prostate; green circle: 
urethra; red pentagram: lesion; vertical lines: therapeutic range. (B) Diagram of 
Hemiablation treatment. (C) Diagram of zonal ablation treatment. (D) Diagram of 
targeted HIFU treatment. Blue dotted edge: incised prostate; blue pentagram: 
recurrent lesion. 
Figure 3. PSA kinetics and functional outcomes of prostate cancer patients under 
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non-whole-gland HIFU and Whole-gland HIFU.  
(A) PSA kinetics of non-whole-gland HIFU at preoperative 0 month, postoperative 3, 
6, and 12 months. (B) PSA kinetics of whole-gland HIFU at preoperative 0 month, 
postoperative 3, 6, and 12 months. (C) IPSS is affected at 1, 3, and 12 months after 
non-whole-gland HIFU treatment, in contrast with preoperation (*p<0.05). (D) IPSS 
is affected at 1, 3, and 12 months after whole-gland HIFU treatment, in contrast with 
preoperation (*p<0.05). (E) Effect on erectile function of non-whole-gland HIFU 
treatment using IIEF-5 questionnaire at preoperative 0 month, postoperative 3 and 12 
months. (F) Effect on erectile function of whole-gland HIFU treatment using IIEF-5 
questionnaire at preoperative 0 month, postoperative 3 and 12 months.  
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Diagrammatic depiction of zones of prostate in HIFU treatment from the transverse base, middle, and apex 
plane, respectively.  
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Figure 2. Diagram of four different HIFU treatments for prostate cancer in our centre.  
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Figure 3. PSA kinetics and functional outcomes of prostate cancer patients under non-whole-gland HIFU and 
Whole-gland HIFU.  
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Tables 
Table 1. Clinical baseline characteristics of prostate cancer patients 
with Non whole-gland HIFU and Whole-gland HIFU. 
Variables 
Non-whole-gland HIFU 
Whole-gland HIFU 
p 
Value 
Hemiablation Zonal ablation 
Number 13 12 61  
Age (year) 70.54±8.38 68.67±6.93 73.16±7.65 0.058 
Pre-PSA (ng/ml) 8.54±8.43 8.23±4.96 6.70±5.97 0.290 
Prostate volume (ml) 37.30±8.86 40.25±10.86 30.32±9.40 0.000 
Pre-PVR (%) 7 (53.8) 2 (16.7) 51 (83.6) 0.000 
ADT 1 (7.7) 0 (0.0) 6 (9.8) 0.642 
Clinical T stage     0.255 
T1c (%) 8 (61.5) 11 (91.7) 36 (59.0)  
T2a (%) 4 (30.8) 0 (0.0) 12 (19.7)  
T2c (%) 1 (7.7) 1 (8.3) 13 (21.3)  
Gleason score    0.308 
≤6 (%) 3 (23.1) 4 (33.3) 23 (37.7)  
7a (%) 5 (38.4) 6 (50.0) 15 (24.6)  
7b (%) 3 (23.1) 2 (16.7) 13 (21.3)  
≥8 (%) 2 (15.4) 0 (0.0) 10 (16.4)  
Risk group (D’Amico)    0.099 
Low (%) 2 (15.4) 2 (16.7) 15 (24.6)  
Intermediate (%) 8 (61.5) 10 (83.3) 34 (55.7)  
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High (%) 3 (23.1) 0 (0.0) 12 (19.7)  
Pre-PSA: Preoperative prostate-specific antigen; Pre-PVR: Preoperative prostate volume reduction; ADT: Androgen deprivation therapy 
 
Table 2. The PSA kinetics of prostate cancer patients with Non 
Whole-gland HIFU and Whole-gland HIFU. 
PSA (ng/ml) 
Non-whole-gland HIFU 
Whole-gland HIFU p value 
Hemiablation Zonal ablation 
At 0 months  8.54±8.43 8.23±4.96 6.70±5.97 0.290 
At 3 months 1.85±1.65 2.34±1.80 1.18±1.50 0.026 
At 6 months 1.14±1.03 1.75±1.04 1.46±1.89 0.934 
At 12 months 1.86±1.23 2.42±1.49 1.79±1.85 0.358 
 
Table 3. Elementary tumor control outcomes of prostate cancer 
patients with Non Whole-gland HIFU and Whole-gland HIFU. 
Variables 
Non-whole-gland HIFU 
Whole-gland HIFU p value 
Hemiablation Zonal ablation 
PSA nadir (ng/ml) 1.06±1.06 1.58±1.15 1.06±1.52 0.453 
Time to PSA nadir (month) 4.62±1.56 5.50±2.50 3.84±1.66 0.006 
PSA decreasing rate at 3 
months  
75.4%±16.9% 71.2%±19.6% 79.0%±23.7% 0.285 
PSA decreasing rate at 6 
months 
83.4%±15.3% 70.4%±36.6% 74.9%±29.2% 0.743 
Histological absence of  
11 (84.6%) 9 (75.0%) 52 (85.2%) 0.655 
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prostate cancer (%) 
BDFS (%) 12 (92.3%) 12 (100.0%) 56 (91.8%) 0.820 
No mpMRI measurable 
prostate cancer (%) 
11 (84.6%) 9 (75.0%) 53 (86.8%) 0.633 
BDFS: Biochemical disease-free survival (%); mpMRI: Mutltiparametric magnetic resonance imaging 
 
Table 4. Elementary functional outcomes and adverse events of 
prostate cancer patients with Non Whole-gland HIFU and 
Whole-gland HIFU. 
 
Non-whole-gland HIFU 
Whole-gland HIFU p value 
Hemiablation Zonal ablation 
IPSS      
At 0 month 4.69±2.29 5.08±3.42 5.20±4.33 0.691 
At 1 month 8.62±2.87 8.67±4.44 10.85±6.10 0.042 
At 3 months 5.38±3.45 5.50±2.71 6.21±5.07 0.389 
At 12 months 4.92±2.22 4.17±2.12 5.36±4.36 0.268 
Temporary Urinary retention 
(%) 
2 (15.4) 3 (25.0) 27 (44.3) 0.035 
Urinary tract infection (%) 1 (7.7) 0 (0.0) 9 (14.8) 0.297 
Pad-free (%)     
At 0 month 13 (100.0) 12 (100.0) 60 (98.4) 1.000 
At 3 months 12 (92.3) 11 (91.7) 53 (86.9) 0.763 
At 12 months 12 (92.3) 11 (91.7) 59 (96.7) 0.704 
Pad-free and leakage-free (%)     
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At 0 month 13 (100.0) 11 (91.7) 54 (88.5) 0.500 
At 3 months 10 (76.9) 11 (91.7) 48 (78.7) 0.792 
At 12 months 12 (92.3) 11 (91.7) 55 (90.2) 1.000 
IIEF-5     
At 0 month 18.92±4.15 19.83±2.89 18.47±3.65 0.307 
At 3 months 12.92±4.75 13.08±5.26 12.06±4.47 0.395 
At 12 months 15.53±4.96 15.75±5.08 15.15±4.57 0.663 
Urinary stricture (%) 1 (7.7) 0 (0.0) 16 (26.2) 0.040 
Fistula (%) 0 (0.0) 0 (0.0) 2 (3.3) 0.898 
Intra-abdominal abscess 0 (0.0) 0 (0.0) 1 (1.6) 1.000 
 IPSS: International prostate symptom score; IEFF-5: International index of erectile function-5; 
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journal homepage: www.europeanurology.com[2_TD$DIFF]Letter to the [3_TD$DIFF]EditorRe: Sumanta K. Pal, Guru Sonpavde, Neeraj Agarwal,
et al. Evolution of Circulating Tumor DNA Profile from
First-line to Subsequent Therapy in Metastatic Renal
Cell Carcinoma. Eur Urol 2017;72:557–64
Pal and coworkers [1] identified changes in the circulating
tumor DNA (ctDNA) profile in patients with metastatic
renal cell carcinoma (mRCC) and ctDNA fluctuations during
first-line and post first-line targeted therapy using a
HiSeq2500 sequencing system. To little surprise, a high
yield of genomic mutations (79%) was observed in this
heterogeneous enrichment malignancy, with gene muta-
tions of TP53 (35%), VHL (23%), EGFR (17%), NF1 (16%), and
ARID1A (12%). The results indicate a significant increase in
mutation frequency in mRCC patients receiving targeted
therapy for subsequent therapeutic lines when compared
to first-line treatment, especially for TP53 (49%vs 24%),VHL
(29% vs 18%),NF1 (20% vs 8%), EGFR (15% vs 8%), and PIK3CA
(17% vs 8%). This largest study to date on ctDNA in mRCC
revealed that liquid biopsy has promise for guiding
targeted therapy. However, we feel that these results
deserve to be reconsideredwith a view to revealing hidden
information behind this methodologically well-conducted
study.
Initially, the authors concluded that the frequency of
ctDNA mutations was higher in the post–first-line than in
the first-line setting. From basic principles, it is known
that the level of ctDNA mutations in the bloodstream is
determined by both release from tumor cells undergoing
necrosis, apoptosis, and active secretion, and engulfment
of scavenger cells such as macrophages [2]. However, a
subtle fact is that VEGF inhibitors could induce apoptosis
of renal cancer cells [3]. Hence, there is a great possibility
that the increase in mutation frequency partly results
from an increase in release caused by the inhibitor itself
rather than real changes in the tumor, and this probably
accounts for a considerable portion because of the large
tumor burden in mRCC. Moreover, mTOR inhibitors,
another major class, are responsible for induction of
macrophage inhibition, and even selective macrophage
death [4]. This apparently indicates that a decrease in
phagocytosis, as another confounding factor, may alsoDOI of original article: http://dx.doi.org/10.1016/j.eururo.2017.03.046.
http://dx.doi.org/10.1016/j.eururo.2017.07.009
0302-2838/# 2017 European Association of Urology. Published by Elsevieraffect the mutation frequency. Therefore, the increase in
mutation frequency could possibly be an ‘‘illusion’’ and
might not totally reflect real levels of ctDNA, which seems
to be ignored by the authors, and new mutations may be
relatively more instructive.
In addition, a recent study suggested that the liver and
kidney are also involved in clearance of ctDNA [5]. Thus, we
recommend that the authors reanalyze their data and
consider intrinsic clearance and the glomerular filtration
rate, which were not taken into account in their study, to
obtain more comprehensive findings.
Furthermore, mutations for three significant genes,
PBRM1, BAP1, and KDM5C, are potentially associated with
outcomes for crossover of targeted therapy according to a
previous study [6], but these are not included in the
Guardant360 testing system. This disparity may introduce
bias when urologists use the Guardant360 platform to test
for ctDNA in mRCC.
In general, despite the merits of ctDNA in overcoming
heterogeneity via a scalpel-free method with real-time
analysis, many impact factors need to be taken into
consideration for use in clinical practice, especially for
guiding targeted therapy in mRCC patients.
Conﬂicts of interest: The authors have nothing to disclose.
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